

**FEDERAL BUREAU OF PRISONS  
CLINICAL PRACTICE GUIDELINES FOR THE PREVENTION AND  
TREATMENT OF VIRAL HEPATITIS  
February 2003**

---

**PURPOSE**

The Federal Bureau of Prisons Clinical Practice Guidelines for the Prevention and Treatment of Viral Hepatitis provide recommendations for the medical management of Federal inmates who have viral hepatitis or who are otherwise at risk of infection.

**REFERENCES**

**General**

Centers for Disease Control and Prevention, Prevention and control of infections with hepatitis viruses in correctional settings, *MMWR* 2003;52(No. RR-1):1-36.

Centers for Disease Control and Prevention, Recommendations for preventing transmission of bloodborne pathogen infections among chronic hemodialysis patients, *MMWR* 2001;50(No. RR-5):1-43.

Centers for Disease Control and Prevention, Practice recommendations for health-care facilities implementing U.S. Public Health Service guidelines for management of occupational exposures to bloodborne pathogens, *MMWR* 2001;50(No. RR-11):1-42.

Centers for Disease Control and Prevention. Guidelines for Viral Hepatitis Surveillance and Case Management.  
[www.cdc.gov/ncidod/diseases/hepatitis/resource/surveillance](http://www.cdc.gov/ncidod/diseases/hepatitis/resource/surveillance).

**Hepatitis A**

Centers for Disease Control and Prevention, Prevention of

hepatitis A through active or passive immunization, Recommendations of the Advisory Committee on Immunization Practices (ACIP), *MMWR* 1999;48(No. RR-12):1-37.

## **Hepatitis B**

Conjeevaram HS, Lok ASF. Management of chronic hepatitis B. *J Hepatology* 2003;38:S90-S103.

Lok ASF, McMahon BJ. Chronic hepatitis B. *Hepatology* 2001;34(6):1225-1241.

Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. *N Engl J Med* 2003;348:808-816.

Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis e antigen-negative chronic hepatitis B. *N Engl J Med* 2003;348:800-807.

Centers for Disease Control and Prevention, Immunization of health-care workers, Recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Hospital Infection Control Practices Advisory Committee (HICPAC), *MMWR* 1997;46(RR-18).

Centers for Disease Control and Prevention, Hepatitis B virus:

A comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination, recommendations of the Immunization Practices Advisory Committee (ACIP) *MMWR* 1991;40(No. RR-13):1-25.

Centers for Disease Control and Prevention, Hepatitis B outbreak in a state correctional facility, 2000, *MMWR* 2001;50:(No.25):529-532.

## **Hepatitis C**

Seeff LB, Hoofnagle JH. National Institutes of Health Consensus Development Conference: Management of hepatitis C: 2002, *Hepatology* 2002;36:S1-S14.

National Institutes of Health Consensus Development Panel  
Statement: Management of hepatitis C. *Hepatology* 1997;26:2S-10S.

Lauer GM, Walker BD. Hepatitis C infection, *N Engl J Med*, 2001;345:41-52.

Centers for Disease Control and Prevention, Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. *MMWR* 2003;52(No. RR-3):1-16.

Di Bisceglie AM, Hoofnagle JH. Optimal therapy of hepatitis C. *Hepatology* 2002;36:S121-S127.

Zeuzem SZ, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. *N Engl J Med* 2000;343:1666-1672.

Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. *Lancet* 2001;358:958-965.

Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med* 2002;347:975-982.

Fontana R, Lok ASF. Noninvasive monitoring of patients with chronic hepatitis C. *Hepatology* 2002;36:S57-S64.

Gebo KA, Herlong HF, Torbenson MS et al. Role of liver biopsy in management of chronic hepatitis C: A systemic review. *Hepatology* 2002;36:S161-S172.

Ghany MG, Kleiner DE, Alter H, et al. Progression of fibrosis in chronic hepatitis C. *Gastroenterology* 2003;124:97-104.

Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. *Hepatology* 2002;36:S47-S56.

Bacon BR. Treatment of patients with hepatitis C and normal serum aminotransferase levels. *Hepatology* 2002;36:S179-S184.

Shiffman ML. Retreatment of patients with chronic hepatitis C. *Hepatology* 2002;36:S128-S133.

Thomas DL. Hepatitis C and human immunodeficiency virus infection. *Hepatology* 2002;36:S201-S209.

Sulkowski MS, Thomas DL. Hepatitis C in the HIV-infected person. *Ann Intern Med* 2003;138:197-207.

Fernandez-Villar A, Sopena B, Vazquez R, et al. Isoniazid hepatotoxicity among drug users: The role of hepatitis C. *Clin Infect Dis* 2003;36:293-298.

Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. *N Engl J Med* 1999;341:556-562.

Centers for Disease Control and Prevention, Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. *MMWR* 1998;47(No. RR-19):1-39.

## **Cirrhosis**

Wright TL. Treatment of patients with hepatitis C and cirrhosis. *Hepatology* 2002;36:S185-S194.

Heathcote EJ, Shiffman ML, Cooksley WGE, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. *N Engl J Med* 2000;343:1673-1680.

Gebo KA, Chander G, Jenckes MW, et al. Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C:

A systemic review. *Hepatology* 2002;S84-S92.

Menon KVN, Kamath PS. Managing the complications of cirrhosis. *Mayo Clin Proc* 2000;75:501-509.

Sharara AI, Rockey DC. Gastroesophageal variceal hemorrhage.

*N Engl J Med* 2001;345:669-681

Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. *Hepatology* 2001;33:464-470.

Wiesner R, Edwards E, Freeman R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. *Gastroenterology* 2003;124:91-96.

INDEX	PAGE
<u>PROCEDURES</u>	
1. HEPATITIS A - TRANSMISSION OF HAV INFECTION	13
2. HEPATITIS A - NATURAL HISTORY OF HAV INFECTION	13
3. HEPATITIS A - DIAGNOSIS	13
4. HEPATITIS A - TREATMENT	14
5. HEPATITIS A - PREVENTION OF HAV INFECTION	14
Vaccine administration	14
Vaccine indications	14
6. HEPATITIS A - INFECTION CONTROL	15
Reporting	15
Containment	15
Contact investigations	15
Post-exposure management	16
7. HEPATITIS B - TRANSMISSION OF HBV INFECTION	17
8. HEPATITIS B - ACUTE HBV INFECTION (Dx/NATURAL HISTORY)	17
9. HEPATITIS B - CHRONIC HBV INFECTION (SCREENING)	18
Screening method	18
Non-sentenced inmates	18
Sentenced inmates	18
10. HEPATITIS B - CHRONIC HBV INFECTION (DIAGNOSIS/COUNSELING)	19
Diagnosis	19
Patient counseling	19
11. HEPATITIS B - CHRONIC HBV INFECTION (NATURAL HISTORY)	20
Chronic HBV infection evolution	20
Chronic hepatitis B flares	21
Chronic HBV complications	21
12. HEPATITIS B - EVALUATION AND TREATMENT OF HBV INFECTIONS	21
Acute hepatitis B	22
Baseline evaluation (chronic HBV infection)	22
Hepatocellular carcinoma (HCC) screening	22
Periodic evaluations (chronic HBV infections)	23

Considerations and evaluation strategy for treatment	23
Treatment indications for chronic hepatitis B	24
Antiviral treatment options for chronic hepatitis B	24
Treatment of chronic hepatitis B with co-morbid conditions	27
Monitoring inmates treated for chronic hepatitis B	27
Discontinuation of antiviral therapy for chronic hepatitis B	28
13. HEPATITIS B - PREVENTION	28
Vaccine program and indications	29
Vaccine administration	29
Inmate workers	30
Hemodialysis patients	31
14. HEPATITIS B - INFECTION CONTROL	31
Patient Education	31
Reporting	32
Containment	32
Hemodialysis	32
Contact investigations	33
Post-exposure management	33
15. HEPATITIS C - TRANSMISSION OF HCV INFECTION	35
16. HEPATITIS C - ACUTE HCV INFECTION (DIAGNOSIS)	35
17. HEPATITIS C - CHRONIC HCV INFECTION (SCREENING)	36
Screening method	36
Non-sentenced inmates	36
Sentenced inmates	36
18. HEPATITIS C - CHRONIC HCV INFECTION (DIAGNOSIS/COUNSELING)	37
Diagnosis	37
Patient counseling	37
19. HEPATITIS C - CHRONIC HCV INFECTION (NATURAL HISTORY)	38
20. HEPATITIS C - EVALUATION AND TREATMENT OF HCV INFECTIONS	39
Acute hepatitis C	39
Baseline evaluation (chronic HCV infection)	39
Hepatocellular carcinoma screening	40
Periodic evaluations (chronic HCV infection)	40
Assessing antiviral treatment contraindications	40
Treatment considerations and evaluation strategy	41
Identifying candidates for liver biopsy	42
Confirmation of chronic HCV infection prior to liver biopsy	43

Indications for antiviral therapy based on liver disease	43
HCV genotype determination	44
Measurement of baseline HCV RNA prior to treatment	44
Pretreatment studies and evaluations	44
Treatment options for chronic hepatitis C	45
Interferon/ribavirin side effects and adverse reactions	46
Treatment of chronic hepatitis C with co-morbid conditions	47
Monitoring inmates during tx for chronic hepatitis C	49
Assessing treatment response to antiviral therapy	50
Retreatment of chronic hepatitis C	51
 21. HEPATITIS C INFECTION CONTROL	 51
Patient education	52
Reporting	52
Containment	52
Hemodialysis	52
Contact investigation	52
Post-exposure management	53
 22. HEPATITIS D - TRANSMISSION OF HDV INFECTION	 54
 23. HEPATITIS D - HDV INFECTION (NATURAL HISTORY AND DIAGNOSIS)	 54
Natural history	54
Diagnosis	54
 24. HEPATITIS D - TREATMENT	 54
 25. HEPATITIS D - INFECTION CONTROL	 55
Patient education	55
Reporting	55
Containment	55
Hemodialysis	55
Contact investigation	55
Post-exposure management	56
 26. CIRRHOSIS	 56
Morbidity assessment	56
Preventive measures	57

## ATTACHMENTS

Appendix 1:	Contact Investigation - Acute Hepatitis A	59
Appendix 2:	Inmate Fact Sheet - HBV and HCV Infections	62
Appendix 3:	Interpretation of HBV Serologic Markers	63



Appendix 4:	Evaluation Strategy - Tx of Chronic Hepatitis B	64
Appendix 5:	Antiviral Medications for Chronic Hepatitis B	65
Appendix 6:	Viral Hepatitis Vaccine Doses and Schedules	66
Appendix 7:	Contact Investigation - Acute Hepatitis B	67
Appendix 8:	Management of Hepatitis B Virus Exposures	70
Appendix 9:	Contraindications to Interferon/Ribavirin Therapy	71
Appendix 10:	Evaluation Strategy - Tx of Chronic Hepatitis C	72
Appendix 11:	Antiviral Medications for Chronic Hepatitis C	74
Appendix 12:	Dosage Adjustments for Viral Hepatitis Medications	76
Appendix 13:	Contact Investigation - Acute Hepatitis C	77
Appendix 14:	Resources (Prevention and Tx of Viral Hepatitis)	80
Appendix 15:	Provider Self-Assessment (Prevention and Tx of Viral Hepatitis)	81

---

## **DEFINITIONS**

### **GENERAL DEFINITIONS**

**Clinician** is a physician or mid-level provider.

**Absolute contraindication** is a condition or factor that in and of itself ordinarily precludes a specific intervention.

**Relative contraindication** is a condition or factor that may preclude a specific intervention when considered in conjunction with other criteria.

**Qualitative viral assay** is a nucleic acid test (NAT) used to detect the presence, but not the amount of virus present.

**Quantitative viral assay** is a nucleic acid test (NAT) used to measure the amount of virus present.

**Standard precautions** are protective measures used for all patient/inmate contacts and situations to prevent the spread of infections transmitted by contaminated blood and body fluids. Precautions include the wearing of gloves and other personal protective equipment (personal protective equipment should be an impervious barrier) when soiling is likely; and procedures for protective handling (handling includes the use of puncture-resistant devices and leak-proof protection) of contaminated materials and equipment, and routine cleaning of all contaminated surfaces and equipment.

### **HEPATITIS A**

**Hepatitis A** is an acute viral hepatitis caused by a highly infectious RNA virus that is transmitted primarily by the fecal-oral route and close personal contact. Acute hepatitis A has a mild to fulminant clinical presentation that resolves without progression to chronic infection or chronic hepatitis.

**HAV** is hepatitis A virus, an enveloped RNA virus.

**IgM anti-HAV** is the antibody subclass to HAV that develops with acute infection.

**IgG anti-HAV** are antibodies to HAV that confer immunity.

**Total anti-HAV** are total antibodies to HAV that include IgG and IgM antibody subclasses.

## **HEPATITIS B**

**Hepatitis B** is an acute or chronic viral hepatitis caused by a DNA virus that is transmitted primarily through sexual contact, exposures to blood, and perinatally.

**HBV** is hepatitis B virus, a double-stranded DNA virus.

**HBsAg** is hepatitis B surface antigen, a viral envelope antigen that is detectable during acute or chronic HBV infection.

**HBeAg** is hepatitis e antigen, a secreted, viral antigen of the hepatitis B viral core that is indicative of active viral replication and increased infectiousness.

**Anti-HBs** is the antibody to hepatitis B surface antigen that confers immunity to HBV infection. Anti-HBs is usually detectable after infection with HBV and following vaccination.

**IgM anti-HBc** is the antibody to hepatitis B core antigen that develops with acute HBV infection.

**Total anti-HBc** is the total antibody response to hepatitis B core antigen that is detectable after acute HBV infection and remains detectable during convalescence. Measurement of total anti-HBc is a useful screen for past HBV infection. Total anti-HBc is not detectable following hepatitis B vaccination.

**Anti-HBe** is the antibody to hepatitis e antigen that develops as viral replication and active hepatitis B begin to wane. Development of anti-HBe coincides with the loss of HBe antigen.

## **HEPATITIS C**

**Hepatitis C** is an acute or chronic viral hepatitis caused by an RNA virus that is transmitted primarily by percutaneous contact with blood.

**HCV** is hepatitis C virus, an enveloped, single-stranded RNA

virus.

**Anti-HCV** is the antibody to HCV core and nonstructural proteins that is detectable from several weeks to months after clinical hepatitis.

**Anti-HCV screening assay** is an immunoassay such as an enzyme immunoassay (EIA) or chemiluminescence immunoassay (CIA) used to screen for HCV infection by measuring antibodies to HCV antigens. The detection of anti-HCV by immunoassay with a high signal-to-cutoff ratio, or in a person with risk factors for HCV infection, is highly predictive of HCV infection.

**RIBA** (anti-HCV) is the recombinant immunoblot assay that measures antibodies to HCV antigens through immunoblot technology. Measurement of anti-HCV by RIBA is used as a supplementary, "confirmatory" test for HCV infection for persons without risk factors for HCV infection who have detectable anti-HCV by a screening immunoassay; OR for persons with or without risk factors for HCV infection who have detectable anti-HCV by a screening immunoassay with a low signal-to-cutoff ratio.

**Anti-HCV indeterminate** is a positive anti-HCV screening immunoassay with a supplemental RIBA test that is inconclusive.

**Early viral response (EVR)** after treatment of chronic hepatitis C with pegylated interferon and ribavirin is a minimum two log decrease in the level of HCV RNA after the first 12 weeks of treatment compared to pretreatment levels, as measured by a quantitative nucleic acid test (NAT).

**Sustained viral response (SVR)** after antiviral treatment of chronic hepatitis C is the absence of detectable HCV RNA in the serum 24 weeks after treatment is completed, measured by a qualitative NAT for HCV RNA with a lower limit of detection of 50 IU/ml or less.

## **HEPATITIS D**

**HDV** is hepatitis delta virus, a defective single-stranded RNA virus that requires HBV for structural integrity and replication.

**Hepatitis D or delta hepatitis** is an acute or chronic hepatitis caused by HDV.

**HBV-HDV coinfection** is the simultaneous infection of HBV and HDV.

**HBV-HDV superinfection** is acute HDV infection in a person with preexisting chronic HBV infection (HBsAg-positive).

**HDag** is hepatitis delta antigen.

**IgM anti-HDV** is an antibody subclass to HDV.

**IgG anti-HDV** is an antibody subclass to HDV.

## **CIRRHOSIS**

**Compensated cirrhosis** is cirrhosis of the liver without evidence of severe liver disease, such as ascites, encephalopathy, marked thrombocytopenia, bleeding esophageal varices; and with preserved hepatic synthetic function, (e.g., albumin  $\geq$  3.5 g/dL, total bilirubin  $\leq$  1.5 mg/dL, and prothrombin time international normalized ratio (INR)  $\leq$  1.5).

**Decompensated cirrhosis** is cirrhosis of the liver with evidence of significant liver disease, such as ascites, encephalopathy, marked thrombocytopenia, bleeding esophageal varices; and loss of liver synthetic function, e.g., albumin  $<$  3.5 g/dL, total bilirubin  $>$  1.5 mg/dL, and prothrombin time international normalized ration (INR)  $>$  1.5.)

**MELD or Model for End-stage Liver Disease** is a validated disease severity index that uses age, creatinine, bilirubin, and prothrombin time to predict mortality.

## **PROCEDURES**

### **1. HEPATITIS A - TRANSMISSION OF HAV INFECTION**

HAV is transmitted fecal-orally and is acquired either by person-to-person contact or by the ingestion of contaminated food or water. Persons at risk for HAV infection include persons consuming contaminated food or water, men who have sex with other men, persons who inject illegal drugs, and persons with clotting disorders who require clotting-factor concentrates.

Newly infected persons are most contagious during the 2-week period before the onset of jaundice. The presence of diarrhea increases contagiousness. HAV can be stable in the environment for weeks to months.

The prevalence of prior HAV infection among incarcerated persons is estimated at 22% - 39%. The prevalence of risk factors for acquiring HAV infection, as well community origin, determine the prevalence of HAV infection for any given inmate population. American Indians, Alaskan Natives, and many persons from Latin America, Africa, the Middle East, China, and Southeast Asia, come from communities with endemic HAV infection where infection by early adulthood is the norm.

In the United States, newly acquired cases of HAV infection are declining, but clusters of hepatitis A cases continue to occur through community-wide outbreaks. The incidence of hepatitis A displays marked geographic variability with the highest rates occurring in the Western United States and in large urban areas among men who have sex with men. Institutional outbreaks of hepatitis A have primarily been limited to settings with children and have not involved correctional facilities.

### **2. HEPATITIS A - NATURAL HISTORY OF HAV INFECTION**

The mean incubation period from infection with HAV until the onset of symptoms of acute hepatitis is 30 days (range: 15 - 50 days). Patients may present with jaundice, dark urine, nausea, diarrhea and severe malaise. Acute hepatitis A is usually a self-limited illness, but a small number of patients develop fulminant hepatitis. Chronic HAV infection and chronic hepatitis A do not occur.

### **3. HEPATITIS A - DIAGNOSIS**

Acute hepatitis A is confirmed by a positive serum IgM anti-HAV titer that is detectable within 5 to 10 days after the onset of symptoms and persists up to 6 months after infection. All inmates presenting with symptoms of acute hepatitis should be tested for the presence of IgM anti-HAV, unless evidence of previous HAV infection exists (IgG anti-HAV-positive or total anti-HAV-positive/IgM anti-HAV-negative).

### **4. HEPATITIS A - TREATMENT**

Treatment efforts are supportive for acute hepatitis A, since effective antiviral therapy is unavailable. Fulminant acute hepatitis A may be complicated by protracted nausea and vomiting, dehydration, high fever, impaired consciousness, and liver failure.

### **5. HEPATITIS A - PREVENTION OF HAV INFECTION**

**Vaccine administration:** Hepatitis A vaccine is an inactivated, highly immunogenic vaccine that is administered intramuscularly in the deltoid or gluteal (upper outer quadrant) muscle in a two-shot series, 6 - 12 months apart depending on the vaccine preparation. The two brands of hepatitis A vaccine (HAVRIX®: formulated with a preservative; and VAQTA®: formulated without a preservative) are equally effective and can be considered interchangeable. A bivalent combination vaccine, TWINRIX®, containing hepatitis A (HAVRIX®) and hepatitis B (ENGRIX-B®) antigens, is given on a 0, 1, 6 month schedule, and is equally effective. Vaccination of a person with previous immunity to HAV infection does not increase the risk of adverse events. Hepatitis A vaccine should not be administered to persons with hypersensitivity to alum or components of the vaccine.

**Vaccine indications:** The following inmates should be considered candidates for hepatitis A vaccination:

- Inmates with liver disease or cirrhosis;
- Inmates with chronic HBV and HCV infections (priority should be given to inmates with underlying liver disease);
- Inmates with clotting-factor disorders who are administered clotting-factor concentrates (especially solvent-detergent-

treated preparations);

- Inmates returning to communities with a high incidence of HAV infection who are determined to be at risk of infection on a case-by-case basis;

- Certain at-risk inmates in the context of a hepatitis A outbreak.

**NOTE:** Pre vaccination serologic screening for prior immunity to HAV infection by detecting IgG or total anti-HAV may be cost-effective for populations at high risk for previous HAV infection, such as certain Native American populations and foreign-born inmates from Latin America, Africa, Southeast Asia, and China where HAV infection is endemic, and among inmates 50 years of age or older.

**NOTE:** Hepatitis A vaccine is not routinely indicated or recommended for inmates workers who are plumbers or foodworkers.

**NOTE:** Postvaccination serologic testing for immunity is not indicated since the hepatitis A vaccine is highly protective.

## **6. HEPATITIS A - INFECTION CONTROL**

**Reporting:** Each institution should have a surveillance system for notifiable infectious diseases in accordance with BOP policy. All cases of acute hepatitis A should be reported to State health authorities as required by all the States and the Commonwealth of Puerto Rico. Acute hepatitis A cases should also be reported to the Central Office HSD.

**Containment:** Inmates diagnosed with acute hepatitis A should be considered contagious three weeks before to 10 days after the onset of jaundice for containment and contact investigation purposes. Inmates diagnosed with acute hepatitis A should be managed in accordance with the following guidelines:

- Isolated in a single cell with separate sink and toilet (e.g. observation cell) until 10 days after the onset of jaundice and until clinically improving without diarrhea;

- Immediately removed from any assigned duties as a food



handler;

- Counseled regarding the importance of strict hand washing and other practical infection control measures;

- Managed using standard precautions to prevent fecal-oral transmission when potentially in contact with contaminated body fluids, including wearing gloves or other personal protective equipment;

- Evaluated by a health care provider daily while acutely ill for signs and symptoms of liver failure such as change in mental status, vomiting, and dehydration.

**Contact investigations:** A contact investigation in consultation with local or State public health authorities is required for all inmates with acute hepatitis A who were incarcerated during the incubation period in order to enhance case-finding of other inmates who may be potentially infected with HAV. All food handlers should be evaluated as part of the contact investigation. Public health officials should be directly involved in any potential foodborne outbreak to determine the need for broad-based immunoprophylaxis. A contact investigation tool is attached in **Appendix 1, Contact Investigation - Acute Hepatitis A.**

**Post-exposure management:**

- **Indications:** The following susceptible contacts of the index case should be considered for immunoprophylaxis:

- cellmate(s);

- sexual contacts;

- persons routinely sharing toilet facilities;

- very close contacts such as those who have shared eating utensils and cigarettes;

- other food handlers if source-case was food handler;

- broad-based immunoprophylaxis to inmate population if source-case was food handler (only on a case-by-case basis in consultation with local and State health care authorities).

- **Administration:** Post-exposure prophylaxis is provided by passive immunization with pooled serum immunoglobulin (IG) in accordance with the following guidelines:

- Screening for IgG (or total) anti-HAV is not recommended so that prophylaxis is not delayed;
- IG is administered 0.02 mL/kg intramuscularly in the gluteal or deltoid muscle (single dose);
- IG prophylaxis is not effective unless administered within 2 weeks of exposure;
- Persons with prior hepatitis A vaccination or previously documented natural immunity (IgG anti-HAV+) do not require prophylaxis;
- Hepatitis A vaccination is not recommended for post-exposure prophylaxis. Hepatitis A vaccination may be indicated for inmate populations determined to be a potential future risk of exposure in the context of an investigated outbreak.

## **7. HEPATITIS B - TRANSMISSION OF HBV INFECTION**

HBV is a bloodborne pathogen that is spread through percutaneous and mucosal exposures to infected blood and body fluids that contain blood. Major modes of acquiring HBV infection include injection drug use, sexual intercourse with an infected partner, perinatal transmission from mother to child, chronic hemodialysis, and, certain occupational exposures. Tattooing with shared, contaminated needles or needle-like devices in jails and prisons is another potential mode of HBV transmission, that specifically affects inmate populations. HBV is viable for at least seven days on environmental surfaces.

HBV is commonly transmitted either perinatally or during childhood in parts of the world where the infection is endemic, such as in Asia, the South Pacific, sub-Saharan Africa, and certain populations in the Arctic, South America, and the Middle East.

Persons with chronic hepatitis B infection (HBsAg-positive) although often asymptomatic, can transmit HBV to others. Contagiousness is increased in persons with chronic HBV

infection who are also hepatitis B e antigen-positive (HBeAg-positive).

Outbreaks of acute hepatitis B have occurred in the correctional setting. Infected contacts may be asymptomatic and identified only through contact investigations.

#### **8. HEPATITIS B - ACUTE HBV INFECTION (DIAGNOSIS/NATURAL HISTORY)**

The incubation period of HBV infection from transmission until the onset of symptoms averages between 90 to 120 days (range: 45 - 180 days). Acute hepatitis B occurs in approximately 30% to 50% of infected adults and may be mild, severe, or fulminant. Signs and symptoms of acute hepatitis include fever, jaundice, nausea, abdominal pain, and malaise. Arthritis, serum sickness, and a nonspecific rash may also occur with acute HBV infection and, when present, are helpful diagnostically.

Acute HBV infection is confirmed by the serologic detection of IgM anti-HBc and HBsAg. The detection of HBsAg alone is not diagnostic for acute HBV infection, since persons with asymptomatic chronic HBV infection can be newly infected with other pathogens that cause acute hepatitis. **NOTE:** IgM anti-HBc may persist at detectable levels for up to 2 years in a small subset of acutely infected persons.

#### **9. HEPATITIS B - CHRONIC HBV INFECTION (SCREENING)**

Newly incarcerated inmates should be provided educational information on the transmission, natural history, and medical management of HBV infection by appropriately trained personnel in accordance with BOP policy. The BOP peer-oriented video on infectious diseases, the attached information in **Appendix 2, Inmate Fact Sheet on Hepatitis B and C Viral Infections** and other appropriate patient educational tools can be used to facilitate counseling efforts.

**Screening method:** Screening for HBV infection should be performed by measuring HBsAg (additional HBV serologic tests may be warranted depending on the inmate's medical history)

**Non-sentenced inmates:** Screening for HBV infection in asymptomatic, highly mobile, non-sentenced inmates in BOP detention facilities should only be pursued for specific

medical indications such as inmates who are pregnant or have signs or symptoms of acute or chronic hepatitis. Asymptomatic non-sentenced inmates in BOP detention facilities with histories of injection drug use or other high risk behaviors for HBV infection should be counseled regarding their risk of acquiring HBV infection and the behaviors that will reduce transmission of HBV infection to themselves and others during incarceration and upon release. Referrals to community testing sites should be made when appropriate.

Long-term inmates in BOP detention facilities should be screened for HBV infection in accordance with guidelines for sentenced inmates.

**Sentenced inmates:** The following sentenced inmates should be screened for HBV infection:

- Pregnant inmates (**NOTE:** Routine screening is medically imperative regardless of previous screening results due to the risk of perinatal transmission);
- Inmates with histories of percutaneous exposures to potentially infected blood, such as injection drug use or receiving tattoos or body piercings while in jail or prison;
- Inmates with HIV or HCV infections;
- Asymptomatic inmates with elevated ALT levels of unknown etiology;
- Inmates with high risk behaviors for HBV infection;
- Inmates from countries with extremely high rates of infection (e.g., Africa, Eastern Europe, the Western Pacific and all of Asia with the exception of Japan);
- Inmates on chronic hemodialysis who fail to develop antibodies after two series of vaccinations should be screened monthly (i.e., measure HBsAg);
- As clinically indicated, (e.g. inmates with signs or symptoms of acute or chronic hepatitis).

**NOTE:** Sentenced inmates who have risk factors for chronic HBV infection, but who initially refuse testing, should be counseled periodically regarding the need for testing during

routine patient encounters.

## **10. HEPATITIS B - CHRONIC HBV INFECTION (DIAGNOSIS/COUNSELING)**

**Diagnosis:** The diagnosis of chronic HBV infection is confirmed by the serologic detection of hepatitis B surface antigen (HBsAg) on two separate occasions  $\geq$  6 months apart; or the one time detection of HBsAg, along with total anti-HBc-positive/IgM anti-HBc-negative.

A complicated array of HBV serologic markers are useful, alone or in combination, in characterizing various phases of HBV infection. Serologic markers are outlined in **Appendix 3, Interpretation of Hepatitis B Virus Serologic Markers.**

**Patient counseling:** Inmates diagnosed with chronic HBV infection should be counseled by a health care provider about the natural history of the infection, potential treatment options, and specific measures for preventing transmission of HBV infection to others (during incarceration and upon release), including the following information and recommendations:

- Most persons with HBV infection will remain healthy, but a small number of persons will develop serious liver disease. Talk to your health care provider about your personal health status;
- Drug treatment options for chronic hepatitis B are developing. Medications may or may not be appropriate for you at this time. Talk to your doctor about your specific treatment plan;
- Do not shoot drugs, have sex with other inmates, or get a tattoo or body piercing while in prison;
- Do not share personal items that might have your blood on them, such as toothbrushes, dental appliances, nail-grooming equipment or razors;
- Cover your cuts and skin sores to keep your blood from contacting other persons;
- Before release, talk to a health care provider about specific ways you can reduce the risk of transmitting HBV

infection to others after you are released;

- Upon release, markedly limit alcohol consumption or abstain altogether, and speak to a physician prior to taking any new medications, including over-the-counter drugs such as nonsteroidal anti-inflammatory agents and herbal remedies, that may damage your liver;

- Upon release, do not donate blood, body organs, other tissue or semen;

- Upon release, seek medical attention so that your condition is appropriately monitored and treated.

## **11. HEPATITIS B - CHRONIC HBV INFECTION (NATURAL HISTORY)**

The majority of adults acutely infected with HBV eventually clear HBsAg from the blood and develop antibodies to HBsAg (anti-HBs) that confer long-term protection from reinfection. A subset of persons acutely infected with HBV develop chronic HBV infection (HBsAg-positive for 6 months or longer). The risk of chronic HBV infection is much greater for persons from parts of the world where HBV is endemic and acquired perinatally, such as in Asia with the exception of Japan. Immunosuppressed individuals are also more likely to develop chronic HBV infection.

**Chronic HBV infection evolution:** Persons with chronic HBV infection (HBsAg-positive) may develop **(1) chronic hepatitis, or (2) asymptomatic chronic infection, or (3) resolve their infection spontaneously:**

- **Chronic hepatitis B** is diagnosed by the following four criteria: **(1)** HBsAg-positive for > 6 months; **(2)** Serum HBV DNA >  $10^5$  cps/mL; **(3)** persistent or intermittent elevations in ALT levels; and **(4)** liver biopsy showing necroinflammation score of Knodell  $\geq 4$ ).

**NOTE:** HBV DNA assays are poorly standardized and should be interpreted cautiously. The diagnostic criteria for serum HBV DNA of  $10^5$  cps/mL is somewhat arbitrary, but helps to identify patients with significant infection that is usually associated with liver inflammation.

Chronic hepatitis B can be **HBeAg-positive or HBeAg-negative**. Persons with HBeAg-positive hepatitis are at risk of

progressive liver disease; however, over time, the majority of these patients spontaneously develop antibodies to HBeAg (anti-HBe), and have a chronic asymptomatic infection. Persons with HBeAg-negative chronic hepatitis B, have elevated HBV DNA levels and necroinflammation on liver biopsy despite being HBeAg-negative. HBeAg-negative chronic hepatitis has a fluctuating, less predictable course and occurs more commonly in persons from Asia and Mediterranean countries.

- **Chronic asymptomatic HBV infection:** Certain persons with chronic HBV infection are able to clear HBeAg, associated with a decrease in detectable serum HBV DNA, while remaining HBsAg-positive. They have the following diagnostic criteria: (1) HBsAg-positive for > 6 months; (2) HBeAg-negative/anti-HBe-positive; (3) serum HBV DNA <  $10^5$  cps/mL; (4) persistently normal ALT levels; and (5) liver biopsy confirms absence of significant necroinflammation with a Knodell score <4. These persons with chronic HBV infection are at low risk of developing decompensated cirrhosis.

- **Resolved hepatitis B:** A certain proportion of persons with chronic HBV infection spontaneously clear their infection (approximately 0.5% yearly). Serum HBV DNA levels decrease to undetectable levels (although very low levels may be detectable by PCR), ALT levels normalize, and serum HBsAg disappears.

**Chronic hepatitis B flares:** Clinically apparent flares of hepatitis can occur in persons with chronic HBV infection during the following: spontaneous clearance of HBeAg with development of anti-HBe antibodies, following HBV-HDV (hepatitis delta virus) superinfection, with immunosuppression, and following antiviral therapy for chronic hepatitis B.

**Chronic hepatitis B complications:** Individuals with chronic HBV infection are at increased risk of developing decompensated cirrhosis and hepatocellular carcinoma (HCC). Rates of progression to cirrhosis or HCC are affected by a variety of factors, including: HBeAg positivity, history of alcoholism, co-infections with HIV, HCV, or HDV, and family history of HCC. Nonhepatic complications of HBV infection include membranous glomerulonephritis and polyarteritis nodosa.

## **12. HEPATITIS B - EVALUATION AND TREATMENT OF HBV INFECTIONS**

**Acute hepatitis B:** Treatment efforts are primarily supportive for acute hepatitis B. Fulminant disease, suggested by hemodynamic instability, dehydration, delirium, vomiting, and a rapidly receding liver edge, requires hospitalization and intensive management. Inmates with acute hepatitis B should be monitored during convalescence and thereafter to determine if they develop chronic HBV infection (persistently HBsAg-positive) or clear their infection (anti-HBs-positive).

**Baseline evaluation (chronic HBV infection):** A baseline clinician evaluation should be indicated for inmates who have chronic HBV infection (HBsAg-positive) and should include:

- Targeted history (assess age of initial infection, alcohol and substance abuse history, family history of hepatocellular carcinoma and chronic HBV infection, risks for gastrointestinal bleeding, and symptoms of decompensated cirrhosis);
- Targeted physical examination (assess for evidence of decompensated cirrhosis, such as jaundice, ascites, encephalopathy, asterixes, and peripheral edema);
- Serum ALT, AST, bilirubin, alkaline phosphatase, albumin, prothrombin time, and further diagnostic evaluations as clinically warranted for other potential causes of liver disease, such as hemochromatosis, Wilson's disease, and autoimmune hepatitis;
- CBC with differential and platelet count;
- Renal function assessment (i.e., serum creatinine/BUN);
- HBeAg, anti-HBe;
- HBV DNA nucleic acid test (**NOTE:** HBV DNA assays are poorly standardized; therefore data should be interpreted cautiously);
- Screening for anti-HIV, anti-HCV, and anti-HDV;
- Hepatitis A vaccination (Priority should be given to inmates with underlying liver disease. Prescreening for immunity to HAV, by detecting IgG (or total) anti-HAV, should be considered prior to vaccination for Native American



populations and foreign-born inmates from Latin America, Africa, Southeast Asia, and China where HAV infection is endemic, and for inmates 50 years of age or older.)

**Hepatocellular carcinoma (HCC) screening:** HCC occurs in persons with chronic HBV infection with or without cirrhosis. The optimal HCC screening strategy for patients with chronic HBV infection is uncertain. The following screening strategy should be considered based on available data, in conjunction with case-by-case decision-making:

- Screen the following inmates with chronic HBV infection who are at higher risk for HCC by periodically obtaining a liver ultrasound (e.g., annually) and alpha-fetoprotein (e.g., every 6 months);
- Inmates with cirrhosis;
- Inmates with a family history of HCC;
- Male inmates > 45 years of age;
- Obtain a baseline alpha-fetoprotein screen for otherwise low-risk inmates from countries where chronic HBV infection is endemic and consider periodic repeat alpha-fetoprotein screening (e.g., annually).

**Periodic evaluations (chronic HBV infection):** Clinician evaluations for inmates with chronic HBV infection should be scheduled on a case-by-case basis in consideration of the following:

- **Chronic HBV infection with elevated ALT levels (HBeAg-positive or HBeAg-negative/HBV DNA-positive):** Refer for liver biopsy and possible antiviral therapy and monitor as clinically necessary.
- **HBeAg-positive with normal ALT levels:** Monitor ALT levels every 3 - 6 months/HBeAg annually to determine if patient is developing worsening liver disease or clearing HBeAg (**NOTE:** ALT levels may transiently increase with clearance of HBeAg and the development of anti-HBe).
- **HBeAg-negative/HBsAg-positive (asymptomatic chronic HBV infection):** Monitor ALT levels every 6 - 12 months/HBsAg annually for spontaneous clearance, i.e., resolution of

infection (HBsAg-negative).

- **Resolved chronic HBV infection:** Chronic care clinic evaluations and ongoing monitoring of ALT levels and hepatitis B serologies are not required since the infection has been cleared.

**Considerations and evaluation strategy for treatment:** A thoughtful approach to initiating antiviral therapy for chronic hepatitis B is warranted, since (1) current treatment options have uncertain long-term efficacy; (2) up to 25% of patients spontaneously clear HBV infection without therapy in placebo-controlled trials; and (3) future treatment options may more effective and better defined.

The decision to recommend antiviral treatment should be based on the severity of liver disease, the likelihood of response, existing co-morbid conditions, the potential for adverse reactions, and other relevant patient-specific factors. A strategy for evaluating inmates with chronic HBV infection for antiviral therapy is outlined in **Appendix 4, Evaluation Strategy for the Treatment of Chronic Hepatitis B.**

**Treatment indications for chronic hepatitis B:** Indications for antiviral therapy include the following criteria:

- Chronic HBV infection (HBsAg-positive) documented for at least 6 - 12 months duration;
- Evidence of active viral replication (HBeAg-positive/HBV DNA-positive OR HBeAg-negative/HBV DNA-positive);
- Chronic liver inflammation suggested by elevated ALT levels above upper limit of normal;
- Evidence of necroinflammation on liver biopsy with a score  $\geq 4$ .

Prior to initiating antiviral therapy for chronic hepatitis B, inmates should be evaluated by a physician and screened for complicating co-morbid conditions or other causes of liver disease, including the following: anti-HIV, anti-HCV, anti-HDV, anti-nuclear antibodies (ANA), serum ferritin, pregnancy test for female inmates, and other diagnostic tests as indicated.

A psychiatrist or psychologist evaluation and thyroid function studies are indicated prior to interferon therapy.

**Antiviral treatment options for chronic hepatitis B:**

Interferon alfa, lamivudine, and adefovir are approved by the Food and Drug Administration (FDA) for the treatment of chronic hepatitis B. Drug dosages and side effects are outlined in **Appendix 5, Antiviral Medications for Chronic Hepatitis B**. Specific drug treatment recommendations should be patient-specific with specialist consultation as necessary.

Drug class considerations include the following:

- **Interferon treatment (Roferon-A, Intron-A):** Interferon alfa treatment for chronic hepatitis B is prescribed as 5 million units daily or 10 million units thrice weekly given by subcutaneous injection for 16 - 24 weeks for HBeAg-positive patients. HBeAg-negative patients require 12 months therapy or longer (The optimal duration of therapy in these patients is uncertain). Prednisone priming before initiating therapy is **NOT** recommended. The average response rate to interferon treatment of chronic hepatitis B (HBeAg-positive) is 30 - 40%. Predictors of a favorable response to interferon therapy include the following factors:

- Short duration of disease;
- High pretreatment ALT levels;
- Low serum HBV DNA levels;
- Liver necroinflammation on biopsy;
- Absence of renal failure, HIV infection, or other serious co-morbidity.

**NOTE:** HBeAg-positive responders to interferon treatment usually clear hepatitis B e antigen, but viremia may persist and the long-term clinical outcomes are uncertain.

**NOTE:** Persons with HBeAg-negative/HBV DNA-positive chronic hepatitis B are have lower response rates than HBeAg-positive patients.

**NOTE:** Interferon is contraindicated in patients with decompensated cirrhosis since life-threatening complications

can occur. Interferon should be used very cautiously in patients with compensated cirrhosis since clinical deterioration may occur.

- **Interferon side-effects:** An influenza-like reaction often occurs within 6 - 8 hours of initial treatment with interferon. Fatigue, headache, fever, and myalgias occur commonly. This acute reaction may abate with subsequent treatments and can be partially aborted by premedication with antipyretics. Acetaminophen can be given safely up to 2 gm/day in divided doses. Nonsteroidal anti-inflammatory agents (NSAIDS) should not be prescribed.

Chronic side effects of interferon can include severe fatigue, weight loss, reversible alopecia, irritability, rage, confusion, and neuropsychiatric disorders. Severe and incapacitating depression can occur, even in persons without previous histories of depression. Bone marrow suppression resulting in neutropenia and thrombocytopenia are potentially serious effects of interferon that should be anticipated and monitored closely particularly in patients with cirrhosis or HIV infection. Thyroid dysfunction occurs in approximately 4% of persons treated with interferon and may result in irreversible thyroid dysfunction, even with cessation of drug therapy.

Inmates with side effects to interferon should have their dosage reduced or therapy discontinued depending on the severity of the side effects. Serious sequelae may occur in fewer than 1% of persons receiving interferon treatment and can include: renal failure, pneumonitis, severe bone marrow suppression, visual and hearing loss, retinal hemorrhage, acute psychosis, and suicide.

- **Lamivudine (Epivir HBV®):** Lamivudine is prescribed orally, 100 mg/day for at least 1 year for the treatment of chronic hepatitis B. In persons who are HBeAg-positive, the endpoint of treatment is seroconversion, i.e., the development of anti-HBe. Treatment beyond one year without seroconversion is of uncertain benefit in these patients.

Lamivudine treatment is generally very well tolerated with milder adverse effects than interferon, although serious adverse events including lactic acidosis, hepatomegaly with steatosis, and pancreatitis occur rarely. Lamivudine is renally excreted and dosing, must be adjusted based on creatinine clearance.

**NOTE:** Lamivudine may have some efficacy in treating patients with end-stage liver disease for whom interferon is either contraindicated or potentially harmful, i.e., decompensated or compensated cirrhosis respectively.

**NOTE:** Lamivudine is prescribed at a higher dose (150 mg PO BID) for individuals co-infected with HIV, in the context of a multi-drug antiretroviral regimen.

**NOTE:** The potential benefits of lamivudine therapy are limited by the frequent development of drug resistance. Resistance to lamivudine can develop despite adherence to therapy. The clinical course of patients with chronic hepatitis B and lamivudine resistance is variable and unpredictable. Some patients who develop lamivudine resistance present with acute exacerbations of liver disease, while others develop only elevated HBV DNA and ALT levels comparable to pretreatment values.

- **Adefovir (Hepsera®):** Adefovir dipivoxil, a nucleotide analogue, is prescribed as a 10 mg oral daily dose for the treatment of chronic hepatitis B. Treatment with adefovir results in histologic improvement in liver disease in approximately 50% of patients without the development of drug resistance. Both HBeAg-positive/HBV DNA-positive and HBeAg-negative/HBV DNA-positive patients may benefit from adefovir therapy. The optimal duration of treatment is uncertain (but is at least 48 weeks) and should be determined on a case-by-case basis.

**NOTE:** Severe exacerbations of hepatitis may occur when adefovir is discontinued; therefore, these patients should be monitored closely. Patients should be screened for renal insufficiency and HIV infection prior to initiating therapy.

**NOTE:** Adefovir is generally well tolerated at the 10 mg dose and is not readily associated with the renal toxicity observed at higher doses; however, persons with underlying renal insufficiency remain at increased risk for nephrotoxicity. Potential complications of adefovir therapy include idiosyncratic lactic acidosis and hepatomegaly, and resistance to HIV in persons with undiagnosed or untreated HIV infection.

**Treatment of chronic hepatitis B with co-morbid conditions:**

Inmates with chronic hepatitis B and the following co-morbid conditions warrant special consideration:

- **HBV and HCV co-infection:** Antiviral therapy in this setting should only be initiated after consultation with a specialist, and with great caution, due to the lack of a recommended treatment strategy and the uncertain effects on underlying liver disease;

- **HBV and HIV co-infection:** Antiviral treatment for persons with HBV and HIV infections should be initiated cautiously in consultation with physician experts as necessary. Lamivudine or adefovir treatment in patients co-infected with HIV should only be initiated along with a multi-drug highly active antiretroviral regimen;

- **Renal disease:** Renal insufficiency secondary to glomerulonephritis from HBV infection may respond to interferon therapy, however treatment should be considered in consultation with a physician expert and dosage adjustments made as necessary. Neither adefovir nor lamivudine should be used to treat chronic hepatitis B in patients with renal insufficiency.

**Monitoring inmates treated with antiviral therapy for chronic hepatitis B:**

Inmates should receive clinician evaluations during antiviral therapy for chronic hepatitis B that are generally consistent with the following:

- Clinician evaluations weekly for one month, then monthly thereafter, to assess drug side effects and potential disease complications;

- Psychiatry or psychology evaluations as clinically indicated during interferon treatments;

- ALT at weeks 1, 2, and 4, and at 4 - 8 week intervals thereafter;

- Periodic bilirubin, prothrombin time and other liver function studies as clinically warranted;

- Creatinine and BUN periodically, monthly while on adefovir;

- CBC with differential and platelet count at weeks 1, 2, and 4 and at 4 - 8 week intervals thereafter;

- Thyroid function studies every 3 months during interferon

therapy.

**NOTE:** Transient increases in aminotransferase levels are common during therapy and correlate with immune system clearance of HBV and the disappearance of HBeAg. Mild to moderate increases in liver enzymes should not be an indication for reducing or discontinuing interferon therapy, unless associated with deteriorating liver synthetic function or jaundice.

**Discontinuation of antiviral therapy for chronic hepatitis B:**

Antiviral therapy for chronic hepatitis B should be discontinued in consultation with a specialist. Severe exacerbations of liver disease can occur with the cessation of antiviral therapy, including adefovir. The effectiveness of treatment is determined by measuring the following parameters 6 months after the completion of antiviral therapy:

- Absence of HBeAg;
- Absence of HBV DNA;
- Normalization of ALT.

**NOTE:** HBeAg may not disappear for months or longer after the completion of effective antiviral therapy. HBsAg may remain positive and HBV DNA may remain detectable for years after completion of treatment. The long-term clinical consequences of persistent viremia are uncertain.

**13. HEPATITIS B - PREVENTION**

**Vaccine programming and indications:** Each institution should establish a hepatitis B vaccine program for inmates. The BOP is currently targeting the following inmates for hepatitis B vaccination based on risk of infection and co-morbid conditions:

- Inmates on chronic hemodialysis or inmates with evolving end-stage renal disease for whom future hemodialysis is anticipated;
- Pregnant women (previously unvaccinated HBsAg-negative mothers);
- As a component of post-exposure prophylaxis for unprotected inmates following percutaneous or permucosal exposures to

blood;

- Inmate workers at risk for bloodborne pathogen exposure in accordance with the institution's exposure control plan and applicable federal regulations;
- Contacts of inmates diagnosed with acute hepatitis B in the context of a contact investigation;
- Inmates with HIV infection with risk factors for acquiring HBV infection;
- Inmates with chronic HCV infection (priority should be given to inmates with liver disease);
- Inmates with cirrhosis or liver disease;
- Inmates at risk for HBV infection due to a history of high risk behaviors, such as injection drug use, unprotected sex with multiple partners, and men who have sex with men.

**Vaccine administration:** Hepatitis B vaccine is available as ENGERIX-B® or RECOMBIVAX HB®. The products are interchangeable; i.e., a vaccination series begun with one product may be completed with the other. Hepatitis B vaccine is also available in a combined formulation with hepatitis A vaccine, TWINRIX®. Viral hepatitis vaccines are listed in **Appendix 6, Viral Hepatitis Vaccine Doses and Schedules**. Hepatitis B vaccination should be administered in accordance with the following guidelines:

- Pre vaccination serologic screening for immunity to HBV infection is not routinely recommended, but should be considered on a case-by-case basis. Serologic screening is only cost-effective if the probability of prior immunity is high, such as in inmates who have undocumented prior hepatitis B vaccination (screen for anti-HBs) and in inmates from countries where HBV infection is endemic (e.g., such as in Asia, the South Pacific, sub-Saharan Africa, and certain populations in the Arctic, South America, and the Middle East);
- A previous anaphylactic reaction to baker's yeast or previous vaccination, is a contraindication to vaccination or booster vaccination;
- Pregnancy should not be considered a contraindication to



vaccination for women at risk of acquiring HBV infection, since HBV itself poses a significant risk to the fetus or newborn. (**NOTE:** No apparent risk exists for adverse effects to developing fetuses when hepatitis B vaccine is administered to pregnant women. Pregnant inmates who are candidates for vaccination should be counseled regarding the risks and benefits of vaccination during pregnancy.)

- All inmate candidates for vaccination should receive counseling by a physician or otherwise qualified health care provider on the administration and potential adverse reactions of hepatitis B vaccination. Counseling, consent, and declination should be documented as per BOP policy;

- The three-dose vaccination series is ideally administered at 0, 1, and 4 - 6 months, however there is significant flexibility with the administration of the complete series with the following guidelines: there must be at least a 1 month interval between doses #1 and #2; and at least a 2 month interval between doses #2 and #3; and at least a 4 month interval between doses #1 and #3. If a dose is delayed the next dose should be administered without restarting the entire series;

- The vaccine is administered intramuscularly in the **deltoid** muscle;

- Postvaccination testing (anti-HBs) to determine antibody responder status is not routinely indicated for newly vaccinated inmates unless future exposures to HBV are anticipated, e.g, inmates receiving hemodialysis and certain inmate workers.

**Inmate workers:** Inmate workers with potential exposures to infectious blood or body fluids as determined by the institution's bloodborne pathogen exposure control plan should be offered hepatitis B vaccination in accordance with BOP policy. Newly vaccinated inmate workers should have anti-HBs levels measured 1 - 2 months after the third dose of vaccine. Inmates with low levels of anti-HBs (< 10 mIU/mL) should receive a second three-dose hepatitis B vaccine series with repeat antibody testing 1 - 2 months after the third dose of vaccine. Inmate workers who still have low levels of anti-HBs after receiving the second hepatitis B vaccine series should be considered nonresponders susceptible to HBV infection and should be counseled regarding appropriate preventive measures and the need for post-exposure HBIG prophylaxis despite

vaccination.

**Hemodialysis patients:** Inmates on chronic hemodialysis are at risk for ongoing exposures to HBV and require hepatitis B vaccination along with close monitoring of their immune status in accordance with the following:

- Inmates on hemodialysis require higher doses of hepatitis B vaccine that are subject to different administration schedules compared to standard hepatitis B vaccine recommendations as enumerated in **Appendix 6**.

- Inmates on hemodialysis who are newly vaccinated for hepatitis B should have anti-HBs measured 1 - 2 months after the last dose of vaccine. Inmates with low levels of anti-HBs (< 10 mIU/mL) should receive a second hepatitis B vaccine series with repeat antibody testing 2 months after the last dose of vaccine. If anti-HBs levels remain low, the inmate should be considered a nonresponder, susceptible to HBV infection and should be counseled regarding appropriate preventive measures. Nonresponders and susceptible inmates who refuse vaccination should be monitored for newly acquired HBV infection while on dialysis by measuring HBsAg, monthly.

- Inmates on hemodialysis with adequate anti-HBs ( $\geq 10$  mIU/mL) following vaccination, but who are anti-HBc negative, should have anti-HBs monitored on an annual basis. A booster dose of vaccine should be administered if the anti-HBs falls below 10 mIU/mL.

- Inmates on hemodialysis with a history of HBV infection (anti-HBc-positive and anti-HBs-positive or HBsAg-positive) do not require anti-HBs monitoring or consideration for vaccination.

- Inmates receiving hemodialysis who test positive for anti-HBc alone could have a false positive test, low-grade chronic infection, remote infection, or resolving acute infection. These hemodialysis patients should be evaluated in accordance with CDC guidelines, per the algorithm in *MMWR* 2001;50(RR-5), to assess their status so that the appropriate monitoring, immunization, and infection control measures can be determined.

#### **14. HEPATITIS B - INFECTION CONTROL**

**Patient education:** All inmates should be counseled during

orientation to the institution and when appropriate during clinical evaluations of the importance of preventing blood exposures to others during activities of daily living such as sharing toothbrushes and razors and through unsafe behaviors such as injection drug use, tattooing, and sexual contact with other inmates.

**Reporting:** Each institution should have a surveillance system for notifiable infectious diseases in accordance with BOP policy. All cases of acute hepatitis B, should be reported to State health authorities as required by all States and the Commonwealth of Puerto Rico. Inmates with chronic HBV infection should be reported to the local and State authorities, as required. All acute cases of hepatitis B and any HBsAg seroconversions among hemodialysis patients should be reported to the Central Office HSD.

**Containment:** Inmates with acute hepatitis B and chronic HBV infection (HBsAg-positive) do not require isolation, but should be counseled on the specific measures necessary for preventing further transmission of HBV to others during incarceration and upon release and should be managed while incarcerated using standard infection control precautions. Non-disposable patient-care items must be appropriately cleaned, disinfected, or sterilized based on the use; and measures must be taken to prevent cross contamination during patient care, e.g., dialysis, vascular access, cauterizing, dental procedures, etc., in accordance with CDC guidelines.

**Hemodialysis:** Infection control measures should be implemented to reduce the transmission of HBV during hemodialysis in accordance with CDC guidelines, i.e., Recommendations for preventing transmission of infection among chronic hemodialysis patients, *MMWR*, 2001;50(RR-5), that include the following:

- **Screening and prevention:** All inmates receiving chronic hemodialysis should be screened for prior HBV infection before admission to the hemodialysis unit by measuring the following serologic markers: HBsAg, total anti-HBc, and anti-HBs. Inmates susceptible to HBV infection should receive hepatitis B vaccine in accordance with CDC guidelines. All inmates who remain susceptible to HBV infection, i.e, nonresponders, should be screened monthly for HBsAg seroconversion, both as a patient care and surveillance measure.

- **Infection control measures:** Institutions that provide dialysis should establish written policies and practices and a mechanism for review, update, and training of staff to ensure that infection control measures to reduce the transmission of HBV during hemodialysis are implemented including the following:

- The use of specifically assigned stations or isolation room, chairs, medications, supplies, and designated staff (do not care for HBV-susceptible inmates at the same time) to separate HBsAg-positive inmates from HBsAg-negative inmates;

- HBsAg-positive inmates should be dialyzed on specifically dedicated machines. Dialyzers from HBsAg-positive inmates should not be reused;

- If it is necessary to reuse a machine used by a HBsAg-positive inmate for a HBsAg-negative inmate, internal pathways of the machine can be disinfected using conventional protocols and extreme surfaces cleaned using soap and water or a detergent germicide;

- All machines and station areas that are used on HBsAg-positive inmates must be terminally cleaned after each use (refer to manufacturers' instructions and CDC recommendations).

**Contact investigations:** A contact investigation is required for inmates diagnosed with acute hepatitis B (IgM anti-HBc-positive), who were incarcerated during the 6 weeks - 6 months prior to disease onset, in order to identify other inmates acutely infected with HBV and better target post-exposure management of asymptomatic contacts. Close contacts should be tested for HBsAg to help identify the source-case. Aggressive "ring vaccination" of close contacts is warranted. The contact investigation should be coordinated with local and State health departments. A contact investigation tool is attached in **Appendix 7, Contact Investigation - Acute Hepatitis B.**

Asymptomatic inmates with positive IgM anti-HBc serologies should be first evaluated to assess if the inmate was symptomatic with acute hepatitis B or infected with HBV before or after incarceration. (IgM anti-HBc can remain positive up to two years after acute infection.) A contact investigation should be pursued if HBV infection was acquired while the

inmate was incarcerated. If the infection was acquired prior to incarceration the local and State health authorities should be notified as required.

**NOTE:** Inmates diagnosed with chronic HBV infection (HBsAg-positive) should be interviewed at the time of diagnosis and periodically thereafter during chronic care visits to determine if they have exposed other inmates to infected blood through sharing toothbrushes and razors, through injection drug use, tattooing, or sexual contact with other inmates. Identified contacts should be considered for post-exposure prophylaxis.

**Post-exposure management:** Inmates with percutaneous (e.g., injection drug use, tattooing, injury with needle or needle-like device contaminated with blood of unknown origin) or mucosal (e.g., sexual contact, human bites) exposures to blood warrant emergent evaluation for post-exposure prophylaxis.

**NOTE:** In evaluating human bites, both the person bitten and the biter should be considered exposed to blood.

- **Emergent care:** Wounds and skin sites that have been in contact with blood or bloody body fluids should be washed with soap and water. Exposed mucous membranes should be flushed with water. Squeezing the wound and treating with topical antiseptics are not recommended.

- **Counseling:** Inmates with percutaneous or mucosal exposures to blood should be assessed by a health care provider and counseled regarding their risk of HBV infection, the natural history of HBV infection, and the recommendations for post-exposure prophylaxis.

- **Post-exposure interventions:** Prompt post-exposure prophylaxis should be provided to inmates potentially exposed to HBV in accordance with the following:

- Unvaccinated inmates should begin the vaccine series immediately and subsequent doses should be administered in accordance with standard practices. Exposed inmates who have already begun, but not completed the vaccine series, should receive subsequent vaccine doses as previously scheduled;

- The source of the exposure should be tested for HBsAg, even if that person was previously vaccinated;

- If the source of the exposure is HBsAg-positive, hepatitis B immunoglobulin (HBIG) 0.06 mL/kg body weight should also be administered to unvaccinated exposed inmates, as soon as possible but  $\leq 7$  days after the exposure. (**NOTE:** When administered simultaneously, hepatitis B vaccine and HBIG should be given intramuscularly at separate sites, with the vaccine administered in the deltoid muscle);
- Inmates who have been fully vaccinated prior to an exposure to HBV ordinarily do not require post-exposure prophylaxis;
- Inmates who have been fully vaccinated prior to an exposure to HBV may warrant a vaccine booster and/or HBIG, as outlined in **Appendix 8, Management of HBV Exposures**, if their anti-HBs responder status has previously been determined (e.g., hemodialysis patients, certain inmate workers); or their responder status is newly assessed because of unique circumstances surrounding the exposure;
- In the context of a contact investigation of acute hepatitis B cases, both hepatitis B vaccination and HBIG are indicated for inmates who have had percutaneous or mucosal exposures to blood; whereas hepatitis B vaccination alone is indicated for other close inmate contacts who have not had direct percutaneous or mucosal exposures.

## **15. HEPATITIS C - TRANSMISSION OF HCV INFECTION**

HCV is a single-stranded, enveloped, RNA virus with 6 genotypes and more than 50 subtypes. Genotype 1 is predominant in the United States.

HCV is transmitted primarily by direct percutaneous exposures to infectious blood such as through injection drug use or the transfusion of contaminated blood products (prior to screening in July 1992). HCV is inefficiently transmitted through sexual contact; however, persons with a history of sexually transmitted diseases and/or multiple sexual partners have an increased risk of acquiring HCV infection. HCV is transmitted from mother to child in approximately 4% - 7% of pregnant women who have chronic HCV infection at the time of delivery. Breast-feeding does not transmit HCV from an infected mother to her child. Tattooing with shared, contaminated needles or needle-like devices in jails and prisons is a potential mode of HCV transmission that may affect inmate populations. Intranasal cocaine use may be a risk factor for acquiring HCV

infection, but its exact role in transmission remains ill-defined. HCV is not spread by sneezing, hugging, coughing, food or water, sharing eating utensils or drinking glasses, or through other casual contact.

#### **16. HEPATITIS C - ACUTE HCV INFECTION (DIAGNOSIS)**

The mean incubation time from the transmission of HCV infection to the onset of symptoms is 6 - 7 weeks (range: 2 - 26 weeks), however, only 20% - 30% of newly infected persons are symptomatic. Acute hepatitis C is rarely severe, but patients may be ill with jaundice, nausea, anorexia, and malaise. Serum ALT levels increase 4 to 12 weeks after acute HCV infection. Antibodies to HCV may or may not be present when symptoms develop or with elevations in ALT levels, however, after 3 months of HCV infection, anti-HCV is detectable by immunoassay in 90% of patients.

The diagnosis of acute hepatitis C is confirmed by: **(1)** marked elevations in ALT with or without symptoms of acute hepatitis; **(2)** negative tests for acute hepatitis A (IgM anti-HAV) and acute hepatitis B (IgM anti-HBc); and **(3)** a positive anti-HCV screening immunoassay that is confirmed by supplemental testing (RIBA) or a high immunoassay signal-to-cut-off ratio. HCV RNA may be detected by a nucleic acid test (NAT) in the blood 1 to 3 weeks after exposure, but viremia may be transient, i.e., a negative NAT for HCV RNA does not preclude acute HCV infection.

#### **17. HEPATITIS C - CHRONIC HCV INFECTION (SCREENING)**

Newly incarcerated inmates should be provided educational information on the transmission, natural history, and medical management of HCV infection by appropriately trained personnel in accordance with BOP policy. The BOP peer-oriented video on infectious diseases, the attached information in **Appendix 2, Inmate Fact Sheet on Hepatitis B and C Viral Infection**, and other appropriate patient educational tools should be used to facilitate counseling efforts.

**Screening method:** The preferred screening test for HCV infection is an immunoassay (e.g., EIA or CIA) that measures antibodies to HCV antigens.

**Non-sentenced inmates:** Screening by immunoassay for HCV infection in asymptomatic, highly mobile, non-sentenced inmates should ordinarily not be pursued unless specifically

indicated for medical reasons (e.g., symptomatic inmates, post-exposure management). Asymptomatic non-sentenced inmates in BOP detention facilities with histories of injection drug use or other high risk behaviors for HCV infection, should be counseled regarding their risk for HCV infection and behaviors that will reduce transmission of HCV infection to others during incarceration and upon release. Referrals to community HCV-testing sites should be made when appropriate.

Long-term inmates in BOP detention facilities should be screened for HCV infection in accordance with guidelines for sentenced inmates.

**Sentenced inmates:** An anti-HCV screening immunoassay, should be considered for the following sentenced inmates:

- Inmates who have injected illicit drugs;
- Inmates who have received a blood transfusion or organ transplant before 1992; or a clotting factor transfusion prior to 1987;
- Inmates on chronic hemodialysis (screen ALT levels monthly and for anti-HCV by immunoassay semiannually);
- Inmates who have received tattoos or body piercings while in jail or prison;
- Inmates with HIV infection or chronic HBV infection;
- Inmates with elevated ALT levels of unknown etiology;
- As clinically indicated, e.g., inmates with signs or symptoms of acute or chronic hepatitis and inmates with percutaneous exposures to blood.

**NOTE:** Sentenced inmates who have risk factors for HCV infection, but initially refuse testing, should be counseled periodically regarding the need for testing during routine patient encounters.

## **18. HEPATITIS C - CHRONIC HCV INFECTION (DIAGNOSIS/COUNSELING)**

**Diagnosis:** The detection of anti-HCV by a screening immunoassay with a high signal-to-cutoff ratio, or in a person with risk factors for HCV infection strongly predicts HCV infection. Inmates with a positive anti-HCV screening



immunoassay with a low signal-to-cutoff ratio, or inmates without risk factors for HCV infection (if no signal-to-cutoff ratio measured) should have a supplemental RIBA test.

An anti-HCV indeterminate result is reported when the screening immunoassay is positive but the supplemental RIBA is inconclusive, suggesting either resolving acute infection, chronic HCV infection, or a false-positive screening immunoassay. The correct diagnosis can usually be determined by obtaining a NAT for HCV RNA then 1 - 2 months later measuring anti-HCV by immunoassay and a NAT for HCV RNA.

The detection of anti-HCV does not differentiate between chronic HCV infection and resolved infection. Chronic infection is confirmed by detecting HCV RNA by a qualitative NAT for at least 6 months. HCV RNA detection is not ordinarily necessary at the time of initial diagnostic screening for inmates with risk factors for HCV infection or evidence of liver disease. However, HCV RNA detection by a qualitative NAT, with a lower limit of detection of 50 IU/mL or less, is essential prior to initiating antiviral therapy.

**NOTE:** A single negative NAT for HCV RNA does not preclude chronic infection. The appropriate processing of NAT samples is also essential, since viral RNA is unstable and false negative tests may result from inadequate processing.

**Patient counseling:** Inmates diagnosed with chronic HCV infection should be counseled by a health care provider about the natural history of the infection, potential treatment options, and specific measures for preventing transmission of HCV infection to others (during incarceration and upon release), including the following information and recommendations:

- Most persons with chronic HCV infection will remain healthy, but a small number of persons will develop serious liver disease. Talk to your health care provider about your personal health status and risk of liver disease;

- Current drug treatment options for chronic hepatitis C are moderately effective. Newer medications should be available in the future that will improve treatment options. Medications may or may not be appropriate for you at this time. Talk to your doctor about your specific treatment plan;

- Do not shoot drugs, have sex with other inmates, or get a tattoo or body piercing while in prison;
- Do not share personal items that might have your blood on them, such as toothbrushes, dental appliances, nail-grooming equipment or razors;
- Cover cuts and skin sores to keep blood from contacting other persons;
- Before release, talk to a health care provider about specific ways you can reduce the risk of transmitting HCV infection to others after you are released;
- Upon release, markedly limit alcohol consumption or abstain altogether, and speak to a physician prior to taking any new medications, including over-the-counter medications such as nonsteroidal anti-inflammatory drugs (NSAIDS) and herbal remedies, that may damage your liver;
- Upon release, do not donate blood, body organs, other tissue or semen;
- Upon release, seek medical attention so that you receive appropriate monitoring and treatment of your condition.

## **19. HEPATITIS C - CHRONIC HCV INFECTION (NATURAL HISTORY)**

An estimated 50% - 85% of persons infected with HCV develop chronic infection, while 15% - 50% of newly infected persons are able to clear the virus spontaneously. Chronic HCV infection frequently results in high levels of HCV RNA in the blood, ranging from  $10^5$  to  $10^7$  international units (IU)/mL, despite the presence of HCV antibodies. The majority of persons with chronic HCV infection are asymptomatic.

Chronic HCV infection has an unpredictable course that is frequently characterized by fluctuations in ALT levels that may or may not be associated with significant liver disease. Approximately one-third of persons with chronic HCV infection have no evidence of liver disease.

An estimated 10% to 15% of persons with chronic HCV infection develop progressive fibrosis of the liver leading to cirrhosis. High levels of alcohol consumption, older age at the time of infection, HIV infection, chronic HBV infection, and male gender increase the risk of disease progression. The

degree of viremia ("viral load") and the HCV genotype, however, do not affect the progression of liver disease. The degree of ALT elevation does not strongly correlate with the risk of disease progression, but persons who develop cirrhosis are more likely to have marked elevations in serum ALT levels.

Once cirrhosis develops in persons with chronic HCV infection, the risk of hepatocellular carcinoma (HCC) is approximately 1% to 4% per year. HCC is rare without underlying cirrhosis in persons with chronic HCV infection. Nonhepatic manifestations of HCV infection include cryoglobulinemia, glomerulonephritis, lymphoma, rheumatoid symptoms, and porphyria cutanea tarda. These clinical scenarios in inmates should prompt evaluation for chronic HCV infection.

## **20. HEPATITIS C - EVALUATION AND TREATMENT OF HCV INFECTIONS**

**Acute hepatitis C:** Inmates diagnosed with acute hepatitis C should be considered for antiviral therapy in consultation with a physician with expertise in managing hepatitis. Reported data suggest that antiviral therapy is beneficial in treating persons with acute HCV infection, however, the timing and the optimal treatment regimen in this setting are uncertain; therefore treatment decisions should be made on a case-by-case basis.

**Baseline evaluation (chronic HCV infection):** A baseline clinician evaluation should be conducted for all inmates diagnosed with HCV infection and include at least the following:

- Targeted history and physical examination to evaluate for signs and symptoms of liver disease, quantify prior alcohol consumption, determine risk behaviors for acquiring HCV infection, and estimate age of infection;
- Serum ALT, AST, bilirubin, alkaline phosphatase, albumin, prothrombin time, and further diagnostic evaluations as clinically warranted, for other potential causes of liver disease such as hemochromatosis, Wilson's disease, and autoimmune hepatitis;
- CBC with differential and platelet count;
- Renal function assessment (serum creatinine/BUN);
- Anti-HIV by immunoassay;

- HBsAg;

- Hepatitis B vaccination (Serologic prescreening for immunity to HBV infection should be considered for inmates who self-report previous, but undocumented hepatitis B vaccination by measuring anti-HBs; and for inmates from countries where HBV infection is endemic, e.g., Asia, the South Pacific, sub-Saharan Africa, and certain populations in the Arctic, South America, and the Middle East, by measuring total anti-HBc. Inmates with evidence of liver disease should be priority candidates for vaccination.);

- Hepatitis A vaccination (Serologic prescreening for immunity to HAV infection by testing for IgG (or total) anti-HAV should be considered for Native American inmates and foreign-born inmates from Latin America, Africa, Southeast Asia, and China where hepatitis A is endemic, and among inmates 50 years of age or older. Inmates with evidence of liver disease should be priority candidates for vaccination.)

**Hepatocellular carcinoma (HCC) screening:** Inmates with chronic HCV infection without cirrhosis are at low risk for HCC, therefore screening tests are not recommended for these patients. Inmates with chronic HCV infection and cirrhosis are at greater risk for HCC, but the optimal screening strategy for these patients is uncertain. Periodic screening for HCC, with a liver ultrasound (e.g. annually) and serum alpha-fetoprotein (e.g. every 6 months), should be considered for inmates with cirrhosis and HCV infection.

**Periodic evaluations (chronic HCV infection):** Inmates with chronic HCV infection should be monitored periodically in chronic care clinics. The frequency of monitoring should be based on patient-specific factors including candidacy for treatment, the degree of liver disease, and co-morbid conditions.

**Assessing antiviral treatment contraindications:** Inmates with chronic HCV infection who are potential candidates for antiviral therapy should first be assessed for treatment contraindications as listed in **Appendix 9, Contraindications to Interferon or Ribavirin Therapy** and in the drug manufacturers' information.

**NOTE:** Inmates with a history of psychiatric illness or with signs or symptoms of mental illness should be referred to a

psychologist or psychiatrist for assessment. Inmates with serious mental illness should be treated and stabilized prior to pursuing a further work-up for treatment.

**NOTE:** Inmates with evidence of substance abuse, either in the present or the recent past (check urine toxicology screen if drug use is suspected and check Sentry for disciplinary actions related to drug or alcohol use.) should be referred for counseling and assessment prior to considering antiviral therapy.

**Treatment considerations and evaluation strategy:**

- **Detention center/short-term inmates:** Inmate candidates for hepatitis C treatment entering BOP short-term detention facilities should ordinarily not be started on antiviral therapy. Treatment decisions should be deferred until the inmate is sentenced and redesignated or released. Inmates entering BOP custody, who are already on treatment for hepatitis C, should be maintained on antiviral therapy, unless treatment must be discontinued for medical reasons. Consult with a Central Office physician if there are questions regarding continuation of therapy.

- **Long-term (sentenced) inmates:** Treating physicians should weigh the following factors in assessing the appropriateness of treatment and the best timing for initiating treatment as they counsel inmates with chronic HCV infection:

- Only 10%-15% of persons with HCV infection develop significant long term complications of liver disease, usually 20-30 years after initial infection;
- No laboratory parameters definitively predict which persons infected with HCV will develop cirrhosis or will respond to medical therapy;
- The presence of moderate to severe fibrosis and inflammation and necrosis on liver biopsy are currently the best markers for determining who should be offered antiviral therapy for hepatitis C;
- Antiviral therapy for hepatitis C is increasingly effective in clearing viremia and establishing sustained viral response rates (SVR);
- Although current antiviral therapy is usually well

tolerated, serious drug side effects may occur;

- Future treatments for hepatitis C may be more effective and more easily tolerated.

An evidenced-based strategy for evaluating inmates for hepatitis C treatment is outlined in **Appendix 10 - Evaluation Strategy for Treatment of Hepatitis C.**

**Identifying candidates for liver biopsy:** Inmates with chronic HCV infection should be periodically evaluated and have ALT levels monitored to help determine if liver biopsy is warranted in accordance with the following:

- **Normal ALT:** Approximately 30% of persons with chronic HCV infection have normal ALT levels. Inmates with normal ALT levels should have ALT levels remeasured several times over the next 2 to 12 months. Inmates with persistently normal ALT levels (at least 3 normal values over a 6 to 12 month period) with no clinical or laboratory evidence of liver disease, are unlikely to have marked liver inflammation or fibrosis.

**NOTE:** Inmates with persistently normal ALT levels may have resolved HCV infection; therefore a NAT for HCV RNA should be obtained to confirm chronic HCV infection; or if negative, should be repeated to confirm resolved HCV infection.

A liver biopsy is usually not warranted if ALT levels are persistently normal. A targeted history and physical examination should be conducted every 6 to 12 months along with platelet count, AST, ALT, alkaline phosphatase and prothrombin time measurements. A decreased platelet count, an increased AST/ALT (e.g., ratio > 1), a decreasing serum albumin, an increased alkaline phosphatase, or a prolonged prothrombin time may indicate underlying liver disease and warrant further evaluation. Inmates with HIV infection and HCV infection with persistently normal ALT levels may be candidates for liver biopsy on a case by case basis, e.g., need to establish absence or presence of liver disease and need for hepatitis C treatment, in patient who may need to start antiretroviral therapy in the near future.

- **Minimally elevated ALT:** Approximately 40% of persons with chronic HCV infection have minimally elevated ALT levels (< 2 times upper limit of normal). Most of these persons probably have mild liver disease and are at low risk of rapid disease

progression, but the histologic data evaluating this patient population are limited.

Inmates with minimally elevated ALT levels should have ALT levels remeasured over 3 to 6 months and should then be reassessed. The decision to obtain a liver biopsy in these inmates should be made on a case-by-case basis. Other factors to consider include the following:

- Inmates with HIV co-infection and a history of heavy alcohol consumption are at greater risk of developing cirrhosis;
- Inmates who acquired HCV infection at an older age are at greater risk of developing cirrhosis, particularly if HCV infection was acquired after the age of 40. Conversely, persons infected before the age of 20 are at much lower risk of developing cirrhosis.
- Inmates who are incarcerated for long periods of time may benefit from liver biopsy so that a long term treatment plan can be developed.

Inmates who are monitored without liver biopsy should have a targeted history and physical examination every 6 to 12 months along with platelet count, AST, ALT, alkaline phosphatase and prothrombin time measurements. A decreased platelet count, an increased AST/ALT (e.g., ratio > 1), a declining serum albumin, an increased alkaline phosphatase, or a prolonged prothrombin time may indicate underlying liver disease and warrants further evaluation.

- **ALT two times normal or greater:** Inmates with ALT levels two times the upper limit of normal or greater should have ALT measurements repeated at least twice over a 6 month period. Inmates with persistent elevations in ALT levels > twice normal should be referred directly for liver biopsy unless antiviral therapy is contraindicated.

- **Suspected compensated cirrhosis:** Inmates with suspected compensated cirrhosis based on clinical and laboratory parameters should be either referred directly for liver biopsy or treated empirically (without biopsy confirmation) in consultation with a specialist.

**Confirmation of chronic HCV infection prior to liver biopsy:**

Inmate candidates for liver biopsy should have chronic HCV

infection confirmed (if not done previously) through the detection of HCV RNA by a qualitative NAT with a lower limit of detection of 50 IU/mL or less. A single negative test should be repeated since HCV RNA levels may fluctuate.

**Indications for antiviral therapy based on liver disease:**

Antiviral therapy is recommended for patients with chronic hepatitis C and a liver biopsy with portal or bridging fibrosis and at least moderate inflammation and necrosis. Persons with severe liver disease, including compensated cirrhosis, are at higher risk of developing liver complications and should therefore be priority candidates for treatment.

Inmates with normal liver histology or minimal fibrosis should be rebiopsied every one to five years. The timing of follow-up should be made on a case-by-case basis. Inmates with minimal fibrosis and marked hepatocellular necrosis and inflammation should be rebiopsied in one year or considered for treatment on a case by case basis, since these inmates are at greater risk of developing progressive fibrosis.

**HCV genotype determination:** The HCV genotype should be determined before prescribing antiviral therapy for chronic hepatitis C since the specific genotype affects the predicted response to treatment and helps determine the duration of therapy. Persons with genotypes 2 or 3 have a 76% to 82% response rate to pegylated interferon/ribavirin therapy compared to persons with genotype 1, who have a 40% to 45% response rate. All inmates should be considered potential candidates for treatment regardless of genotype. Once the HCV genotype has been determined in a specific patient, serial genotype testing is not indicated, unless reinfection is suspected, since HCV genotypes do not change during the course of an infection.

**Measurement of baseline HCV RNA prior to treatment:** All inmates should have a baseline NAT for HCV RNA prior to treating chronic hepatitis C. The recommended NAT depends on the HCV genotype.

- Inmates with genotype 2 or 3 should have a qualitative NAT with a threshold of detection of 50 IU/mL;
- Inmates with genotype 1 should have a quantitative NAT for HCV RNA (viral load).



**Pretreatment studies and evaluations:** Inmates should be evaluated by a physician and screened for co-morbid conditions that may complicate antiviral therapy.

- **Screening tests:** The following tests should be obtained (unless completed recently): Serum chemistries including liver enzymes, bilirubin, CBC with differential and platelet count, prothrombin time, TSH, renal function, anti-HIV, HBsAg, ferritin, ANA, fundoscopy for inmates with diabetes or hypertension, and other patient-specific diagnostic tests as medically indicated.

- **Pregnancy test for all female inmates:** Ribavirin may cause fetal abnormalities. All female inmates of childbearing potential must have a pregnancy test prior to initiating therapy.

- **Cardiac risk assessment:** Inmates should have a basic cardiac risk assessment from a clinician, since hemolysis from ribavirin may precipitate angina pectoris. Symptomatic inmates should be evaluated for cardiac disease prior to initiating treatment for chronic hepatitis C.

- **Mental health evaluation:** A mental health evaluation should be performed by a psychiatrist or a psychologist before prescribing interferon and ribavirin therapy to determine if mental health treatment is warranted prior to antiviral therapy or if ongoing mental health assessments are needed during treatment.

The evaluation should include an assessment of axis I and axis II diagnoses, including a comprehensive alcohol and substance abuse history, and a suicide risk assessment. Interferon therapy has been associated with changes in mood and affect in most individuals; in a small percentage, significant depression, suicide attempts and completed suicides have resulted. The absence of a history of depression or suicide attempts does not appear to lessen the risk of these side effects from interferon; however their presence should prompt heightened vigilance on the part of the treating providers.

Other mental illnesses or conditions, if not treated or not in remission, may adversely affect the inmate's ability to successfully complete a course of antiviral treatment, either due to issues of compliance or inability to tolerate even mild side effects.

- **Inmates with compensated cirrhosis:** Inmates with suspected or biopsy-confirmed compensated cirrhosis should have an upper endoscopy screening for esophageal varices, a liver ultrasound, and measurements of alpha-fetoprotein and ammonia prior to treatment initiation. If HCC or decompensated cirrhosis is diagnosed, antiviral therapy is contraindicated.

**Treatment options for chronic hepatitis C:** Pegylated interferon (alfa 2a or alfa 2b) plus ribavirin is the preferred drug regimen for treating chronic hepatitis C in the absence of contraindications to either drug. Pegylated interferon is available in two formulations: PEG-Intron® and Pegasys®. Ribavirin is available in two formulations: Rebetol® and Copegus® that are considered bioequivalent by the Food and Drug Administration. Clinical studies have paired pegylated interferon alfa 2a with Copegus®; and pegylated interferon alfa 2b with Rebetol®.

A 24-week course of pegylated interferon and ribavirin is recommended for patients with genotypes 2 or 3; whereas a 48-week course of treatment is required for patients with genotype 1. Patients with genotype 1 require higher doses of ribavirin. The optimal duration of antiviral therapy is unknown for persons with genotypes 4, 5, 6, or nontypable HCV; therefore, these patients should be treated with the 48-week course of treatment recommended for genotype 1 patients. Inmates who have contraindications to ribavirin, regardless of genotype, should be treated with a 48-week course of pegylated interferon alone.

Detailed drug dosages, monitoring parameters, and potential side effects are outlined in **Appendix 11, Antiviral medications for Chronic Hepatitis C** and in **Appendix 12, Dosage Adjustments for Viral Hepatitis Medications**.

**NOTE:** Ribavirin should ordinarily be administered by directly observed therapy to ensure adherence.

**NOTE:** Ribavirin is completely ineffective as monotherapy and should never be prescribed without interferon.

**NOTE:** Patients with compensated cirrhosis have poorer SVR rates with interferon and ribavirin therapy compared to persons with less severe liver disease. Furthermore, once weekly pegylated interferon with ribavirin may not provide more benefit than three times a week interferon with ribavirin

when treating these patients. Inmates with chronic hepatitis C and compensated cirrhosis should be treated in consultation with a physician specialist, since treatment recommendations for these patients are controversial and evolving.

**Interferon/ribavirin side effects and adverse reactions:**

Inmates treated for chronic hepatitis C should be counseled by a clinician before and during treatment regarding both the anticipated and potential side effects/adverse reactions of interferon and ribavirin.

- **Interferon:** An influenza-like reaction often occurs within 6-8 hours of initial treatment with interferon. Fatigue, headache, fever, and myalgias occur commonly. This acute reaction may abate with subsequent treatments and can be partially aborted by premedication with antipyretics. Acetaminophen, can be given safely up to 2 gm/day in divided doses. Nonsteroidal anti-inflammatory agents (NSAIDS) should not be prescribed.

Chronic side effects of interferon can include severe fatigue, weight loss, reversible alopecia, irritability, rage, confusion, and neuropsychiatric disorders. Severe and incapacitating depression can occur, even in persons without previous histories of depression. Bone marrow suppression resulting in neutropenia and thrombocytopenia are potentially serious effects of interferon that should be anticipated and monitored closely particularly in patients with cirrhosis or HIV infection. Thyroid dysfunction occurs in approximately 4% of persons treated with interferon and may result in irreversible thyroid dysfunction, even with cessation of drug therapy.

Inmates with side effects to interferon should have their dosage reduced or therapy discontinued depending on the severity of the side effects. Serious sequelae may occur in less than 1% of persons receiving interferon treatment and can include: renal failure, pneumonitis, severe bone marrow suppression, visual and hearing loss, retinal hemorrhage, acute psychosis, and suicide.

**NOTE:** Pegylated interferons generally have similar side effect profiles compared to standard interferons, however, pegylated interferons do induce neutropenia to a greater degree.

- **Ribavirin:** Ribavirin causes a dose-related red cell

hemolysis to variable degrees in nearly all persons who are treated. A decrease in the hemoglobin of 2 to 3 gm/dL and a decrease in hematocrit of 5% to 10% should be anticipated. Persons with a preexisting hemolysis or severe anemia (hemoglobin < 11 g or hematocrit < 33%) or underlying cardiovascular or cerebrovascular disease should not receive ribavirin. Persons with HIV infection or other co-morbid conditions should be monitored closely. Anemia ordinarily develops between 1 and 4 weeks of initiating therapy. New onset of episodic chest pain during therapy should be presumed to be angina pectoris until proven otherwise. Symptoms of sudden hemolysis such as dyspnea, fatigue, headache, and palpitations may develop. If anemia occurs ribavirin should be reduced in dosage or discontinued.

Ribavirin also causes histamine-like side effects such as nasal stuffiness and itching. More severe effects can include an asthma-like syndrome or bronchitis.

**NOTE: Ribavirin may cause fetal abnormalities. All female inmates of childbearing potential must have a pregnancy test prior to initiating therapy. Both women AND men must be counseled to use adequate birth control during treatment and 6 months after treatment is completed. Counseling of both women AND men regarding the risk of birth defects is particularly important for inmates awaiting release and receiving ribavirin or who have recently completed treatment.**

#### **Treatment of chronic hepatitis C with co-morbid conditions:**

- **Active substance abuse:** Inmates with histories of substance abuse and hepatitis C should be referred for drug education, nonresidential drug treatment, and residential drug treatment, as appropriate and in accordance with BOP policy as a component of their treatment plan. The timing of antiviral therapy and participation in drug treatment programs should be coordinated on a case-by-case basis. Inmates who are treated with antiviral therapy for chronic hepatitis C and then subsequently use illicit drugs or alcohol should be evaluated on a case by case basis to determine if treatment should be discontinued or maintained. The prescribing physician should consider multiple factors including: the effectiveness of antiviral therapy to date, the risk of illicit drugs to the inmate's health, and future adherence concerns to the prescribed antiviral regimen.

Inmates consuming alcohol should be specifically advised of

the following:

- Alcohol use during antiviral treatment decreases the likelihood of a sustained response to treatment;

- The inability of an inmate with a history of alcoholism to abstain from even occasional alcohol ingestion during antiviral treatment is indicative of an unresolved substance abuse problem. Eradication of HCV infection without resolution of alcoholism is unlikely to prevent end-stage liver disease.

- **HBV and HCV co-infections:** Antiviral therapy for inmates with HBV and HCV co-infections should be initiated with great caution, and only in consultation with a specialist, due to the uncertainty of the risks and benefits of treatment and lack of a recommended treatment regimen.

- **HIV and HCV co-infection:** Effective antiretroviral therapy has markedly reduced the incidence of opportunistic infections and related mortality for persons with HIV infection. HCV-related liver disease has now emerged as a serious health concern for many persons with HIV infection. Antiviral therapy should be considered for inmates with chronic hepatitis C and HIV co-infection, since HIV may accelerate the development of fibrosis and subsequent end-stage liver disease. Treatment strategies for persons with chronic hepatitis C and HIV infection are evolving, complicated by immune suppression, and affected by potential drug interactions and toxicities. Treatment decisions for these individuals should therefore be patient-specific, while considering the following:

- Treatment for HIV and HCV infections should not be initiated simultaneously;

- Inmates who have not been treated for either HIV infection or chronic hepatitis C should first be treated with antiretroviral therapy if the inmate is a candidate for treatment (AIDS or CD4+ T-cell count < 350 cells/mm<sup>3</sup>); otherwise consider antiviral therapy for chronic hepatitis C in inmates with documented liver disease;

- Inmates on antiretroviral therapy for HIV infection should be considered for interferon and ribavirin therapy if they have documented liver disease; and if the HIV viral load is undetectable and the CD4+ T-cell count is > 350 cells/mm<sup>3</sup>;

- Persons with HIV infection may be at greater risk of developing hepatotoxicity during interferon and ribavirin therapy. ALT levels should be monitored every 1 - 2 months while on therapy;
- Ribavirin and didanosine (ddI) should not be co-administered due to the increased risk of pancreatitis and lactic acidosis;
- Interferon and ribavirin side effects and drug toxicities may be more clinically significant in patients with HIV infection, (e.g., neuropsychiatric complications, neutropenia, and anemia), however treatment with interferon and ribavirin does not increase the risk of HIV-related opportunistic infections.
- **Latent TB and chronic HCV infection:** Inmates with latent TB infection and chronic HCV infection should be considered for isoniazid treatment and should be monitored for hepatotoxicity in accordance with the same guidelines established for patients without HCV infection. All inmates require frequent screening for symptoms of hepatitis while taking isoniazid. Inmates with baseline ALT elevations warrant periodic monitoring of ALT levels. Isoniazid should be discontinued in inmates with marked elevations in ALT levels or significant signs or symptoms of hepatitis.

#### **Monitoring inmates during treatment for chronic hepatitis C:**

- **Clinician evaluations:** Inmates receiving interferon and ribavirin should receive clinician evaluations weekly for one month, then monthly thereafter, to assess drug side effects and potential complications. Inmates with compensated cirrhosis, HIV infection, and other co-morbid conditions require more frequent monitoring, as do patients who develop significant side effects or complications while on therapy. Psychiatry and psychology consultations should be provided as clinically indicated while inmates are taking interferon.
- **Laboratory monitoring:** Inmates receiving interferon and ribavirin therapy should be monitored for drug toxicities in accordance with the following general guidance:
  - ALT at weeks 1,2, and 4, and at 8 - 12 week intervals thereafter (**NOTE:** An unusual but serious complication of interferon or interferon and ribavirin combination therapy

is the paradoxical worsening of hepatitis. If ALT levels increase significantly, antiviral therapy should be discontinued, ALT levels should be monitored closely, and the inmate should be monitored for signs and symptoms of hepatitis);

- Periodic bilirubin, prothrombin time, and serum chemistries, including creatinine/BUN; repeated with any new elevations in ALT or symptoms or signs of liver disease;

- CBC with differential and platelet count at weeks 1, 2, and 4 and at 4 - 8 week intervals thereafter;

- Thyroid function studies every 3 months during interferon therapy.

**Assessing treatment response to antiviral therapy:** The recommended duration of interferon and ribavirin combination therapy and the assessment of treatment response vary with HCV genotype.

- **Genotype 1 (1a or 1b):** Administer antiviral therapy for 12 weeks and check a quantitative NAT for HCV RNA to assess for early viral response (EVR) (**NOTE:** Use the same laboratory and same type of NAT when comparing pretreatment and post-treatment levels of HCV RNA). A minimum 2 log decrease in viral load after 12 weeks of treatment predicts a sustained viral response (SVR) and warrants continued treatment for another 36 weeks (total 48 weeks course of treatment). Antiviral therapy should be discontinued if HCV RNA levels do not adequately decline after 12 weeks of treatment.

- **Genotypes 2 and 3:** Administer antiviral therapy for 24 weeks in all patients unless complications develop. At the end of treatment, check a qualitative HCV RNA assay to determine treatment response.

- **Assessing SVR (all genotypes):** ALT levels should be obtained every 2 months for 6 months following the completion of antiviral therapy. A follow-up qualitative NAT for HCV RNA should be obtained 24 weeks after the completion of successful therapy in all patients to confirm the efficacy of treatment. Effective antiviral therapy results in a sustained viral response (SVR), defined as the absence of detectable HCV RNA in the serum measured by a qualitative NAT for HCV RNA with a lower limit of detection of 50 IU/ml or less at 24 weeks after

the end of treatment.

### **Retreatment of chronic hepatitis C:**

Patients who do not achieve a SVR following antiviral therapy can be categorized as nonresponders or relapsers.

- **Nonresponders:** These patients do not adequately respond to antiviral therapy by either (1) developing a SVR upon the completion of antiviral therapy or by (2) clearing viremia at a rate that predicts a SVR if treatment were continued.

- **Relapsers:** These patients have undetectable levels of HCV RNA at the end of treatment, but do not attain a SVR, i.e., HCV RNA is detectable by 24 weeks after completion of initially effective antiviral therapy.

Retreatment of relapsers and nonresponders may be considered on a case-by-case basis while considering the following:

- Relapsers should not be retreated with the same regimen;
- Long-term antiviral maintenance therapy is unproven and should not be prescribed.
- Retreatment should be considered for those inmates who are most likely to benefit from therapy and are at significant risk of disease progression by weighing the follow factors in combination:
  - The severity of underlying liver disease determined by liver biopsy;
  - The viral genotype and other predictive factors that influence response rates;
  - The previous regimen and the relative potency of the new regimen;
  - The previous response to therapy.

Retreatment must be approved through Central Office for all cases using the current approval form found in the BOP National Formulary.

## **21. HEPATITIS C - INFECTION CONTROL**



**Patient education:** All inmates should be counseled during orientation to the institution and when appropriate during clinical evaluations of the importance of preventing blood exposures to others during activities of daily living such as sharing toothbrushes and razors and through unsafe behaviors such as injection drug use, tattooing, and sexual contact with other inmates.

**Reporting:** Each institution should have a surveillance system for notifiable infectious diseases in accordance with BOP policy. Acute hepatitis C is a reportable condition in many States. Inmates with acute hepatitis C should be reported to local or State authorities where required and to the Central Office HSD. Inmates with chronic HCV infection should be reported to the local or State health authorities where required.

**Containment:** Inmates with acute hepatitis C and chronic HCV infection do not require isolation, but should be counseled on the specific measures necessary for preventing further transmission of HCV to others during incarceration and upon release and should be managed while incarcerated using standard infection control precautions. Non-disposable patient-care items must be appropriately cleaned, disinfected, or sterilized based on the use; and measures must be taken to prevent cross contamination during patient care, e.g., dialysis, vascular access, cauterizing, dental procedures, etc., in accordance with CDC guidelines.

**Hemodialysis:**

- **Screening:** Inmates on hemodialysis without chronic HCV infection should have serum ALT levels measured monthly and anti-HCV measured by an immunoassay semi-annually to screen for newly acquired HCV infection. All inmates receiving hemodialysis with a positive anti-HCV screening immunoassay should have a supplemental RIBA test performed. Inmates on hemodialysis with unexplained ALT elevations who are repeatedly anti-HCV-negative should be tested for HCV RNA by a NAT.

- **Infection control:** Infection control measures to reduce HCV transmission during hemodialysis should be implemented in accordance with CDC guidelines. Inmates with HCV infection receiving dialysis do not need to be isolated from other patients or dialyzed separately on dedicated machines.

Dialyzers used for inmates with HCV infection can be reused.

**Contact investigation:** Contact investigations should be initiated for those inmates with acute hepatitis C who have been incarcerated during the 2 weeks-6 months prior to disease onset. A contact investigation tool is attached in **Appendix 13, Contact Investigation - Acute Hepatitis C**. In addition to documenting medical visits or procedures during which the inmate may have had blood exposure, inmates should be interviewed for information regarding recent drug injection, tattooing or body piercing and sexual contacts. Enhanced case-finding should be done, and counseling and testing for anti-HCV should be initiated for:

- sexual contacts;
- injection partners;
- others tattooed using same equipment.

**Post-exposure Management:**

- **Emergent care:** Wounds and skin sites that have been in contact with blood or bloody body fluids should be washed with soap and water. Exposed mucous membranes should be flushed with water. Squeezing the wound and treating with topical antiseptics are not recommended.

- **Counseling:** Inmates with percutaneous or mucosal exposures to blood should be assessed by a qualified health care provider and counseled regarding their risk of acquiring HCV infection, the natural history of HCV infection, and the recommendations for post-exposure management.

- **Post-exposure follow-up:** No vaccine or passive immunization is available to prevent acquisition of HCV infection following an exposure. The following guidelines should be used for managing inmate exposures to HCV:

- Whenever feasible, the source of the exposure should be tested for anti-HCV, unless the source's infection status is already known;

- Exposed inmates should be referred for medical evaluation and follow-up;

- Anti-HCV by a screening immunoassay (confirmed by RIBA, if positive) and ALT levels should be measured at 0 and at 4-6 months following an exposure to screen for newly acquired HCV infection;

- HCV RNA may be detectable 1 to 3 months following an exposure to HCV-infected blood, however, since viremia may be transient, the absence of detectable HCV RNA does not preclude acute HCV infection;

- Inmates with evidence of newly acquired HCV infection should be appropriately counseled and referred for further medical evaluation including possible treatment of acute hepatitis C.

## **22. HEPATITIS D - TRANSMISSION OF HDV INFECTION**

HDV is a defective RNA virus that requires HBsAg for structural integrity and replication. HDV is transmitted through percutaneous exposures to blood such as through injection drug usage. Sexual transmission occurs, but is much less efficient than for HBV. Perinatal transmission is rare. Inmates at highest risk for delta hepatitis have a history of injection drug use or have resided in areas of the world with a high prevalence of infection such as Turkey, Egypt, Southern Italy, Spain, Russia, Romania, and the Amazon River Basin.

## **23. HEPATITIS D - NATURAL HISTORY AND DIAGNOSIS**

**Natural history:** Acute HBV-HDV coinfection (concurrent infections with HBV and HDV) results in a severe acute hepatitis more frequently than infection with HBV infection alone, but progression to chronic infection is uncommon. HBV-HDV superinfection (HDV infection acquired in a person with preexisting chronic HBV infection) results in chronic HDV infection in the large majority of persons who are at higher risk for cirrhosis and HCC compared to persons infected with HBV alone.

**Diagnosis:** Serologic detection of HDV infection varies depending on whether the virus is acquired through coinfection or superinfection.

Following HBV-HDV co-infection both IgM anti-HDV and IgG anti-HDV are detectable. IgM anti-HDV is more likely to be detectable during the acute illness; whereas IgG anti-HDV is more like to be present during convalescence, but there is

considerable overlap. Chronic infection is uncommon. IgG anti-HDV is usually undetectable with the disappearance of HBsAg and HDAg.

Following HBV-HDV superinfection, chronic HDV infection with detectable HDAg usually occurs. Both IgM anti-HDV and IgG anti-HDV remain detectable.

#### **24. HEPATITIS D - TREATMENT**

The treatment of acute delta hepatitis is supportive similar to the management of acute hepatitis B.

Periodic clinician evaluations should be conducted for inmates with chronic HDV infection in accordance with guidelines for monitoring chronic HBV infection. Inmates with chronic delta hepatitis should be considered candidates for antiviral therapy using the same criteria as inmates with chronic HBV infection.

**NOTE:** Antiviral therapy for delta hepatitis should be considered in consultation with a specialist. Treatment regimens may differ from those recommended for persons infected with HBV alone.

#### **25. HEPATITIS D - INFECTION CONTROL**

**Patient education:** All inmates should be counseled during orientation to the institution and when appropriate during clinical evaluations of the importance of preventing blood exposures to others during activities of daily living such as sharing toothbrushes and razors and through unsafe behaviors such as injection drug use, tattooing, and sexual contact with other inmates.

**Reporting:** Inmates with acute delta hepatitis should be reported to State and local health authorities as required. Acute delta hepatitis cases should also be reported to the Central Office HSD.

**Containment:** Inmates with acute delta hepatitis or chronic HDV infection do not require isolation, but should be counseled on the specific measures necessary for preventing further transmission of HDV to others during incarceration and upon release and should be managed while incarcerated using standard infection control precautions. Non-disposable patient-care items must be appropriately cleaned, disinfected,

or sterilized based on the use; and measures must be taken to prevent cross contamination during patient care, e.g., dialysis, vascular access, cauterizing, dental procedures, etc., in accordance with CDC guidelines.

**Hemodialysis:** Routine testing for HDV infection for inmates receiving hemodialysis is not recommended. Inmates who are known to be infected with HDV should be isolated from all other dialysis patients, especially those who are HBsAg-positive.

**Contact investigation:** A contact investigation should be conducted for all inmates diagnosed with acute delta hepatitis using a similar approach as that recommended for acute hepatitis C cases (i.e., evaluating potential percutaneous exposures, such as injection drug use or tattooing). Suspected contacts should be tested for HBsAg in order to identify at-risk persons with chronic HBV infection (HBsAg-positive).

**Post-exposure management:** Wounds and skin sites that have been in contact with blood or body fluids should be washed with soap and water. Exposed mucous membranes should be flushed with water. Squeezing the wound or treating with antiseptics is not recommended. Prophylaxis for acute HBV infection should be provided to susceptible contacts. HDV can not infect an individual if infection with HBV is prevented with hepatitis B immunoglobulin/hepatitis B vaccine. Inmate contacts with chronic HBV infection should be counseled on the risk for HBV-HDV superinfection.

## **26. CIRRHOSIS**

**Morbidity assessment:** The Model for Endstage Liver Disease (MELD) predicts liver disease severity and the risk of three month mortality based on serum creatinine, serum total bilirubin, and prothrombin time (INR). In a recent study of patients with end-stage liver disease awaiting liver transplantation, 3 month mortality varied with increasing MELD scores: MELD < 9, mortality was 1.9%; MELD of 20 - 29, mortality was 19.6%, MELD of 30 - 39, mortality was 52.6%; and MELD ≥ 40, mortality was 71.3%.

The value of MELD as a predictor of mortality is limited by its dependency on serum creatinine which can fluctuate with changes in fluid status. MELD is a better predictor of mortality for different populations than of death for any

given individual. Nevertheless, MELD provides useful information for assessing the morbidity of inmates with end-stage liver disease.

All inmates with decompensated cirrhosis should have a MELD score determined to assess mortality risk. MELD scores should be recalculated over several weeks in inmates with shifting fluid status.

The MELD score can be automatically calculated at [www.medcalc3000.com/UNOS.htm](http://www.medcalc3000.com/UNOS.htm). The calculator can also be accessed stepwise through the United Network for Organ Sharing (UNOS) website, [www.unos.org](http://www.unos.org), by selecting resources, then [meldpeldcalculator](#).

Inmates with MELD scores of 30 or greater should be considered for Medical Referral Center designation.

**NOTE:** The MELD score predicts mortality independent of clinical parameters such as hepatic encephalopathy, ascites, and variceal bleeding. These significant complications of cirrhosis, however, should also be considered in referring patients for Medical Referral Center designation.

**Preventive measures:** The following preventive measures should be considered for inmates with cirrhosis:

- Vaccination against influenza (annually), pneumococcal pneumonia, and hepatitis A and B (unless immune);
- Patient education on selecting a low-salt, low fat, "heart healthy" diet;
- Patient education regarding complete abstinence of alcohol during incarceration and after release, and the avoidance of iron supplements and potentially hepatotoxic medications, such as nonsteroidal inflammatory drugs (NSAIDS);
- Baseline endoscopy to screen for esophageal varices (Follow-up annual screening can be considered on a case-by-case basis, but the benefit of repeated screening is unclear. Once esophageal varices have been identified the risk of future variceal hemorrhage is 25% to 35%);
- Nonselective beta-blocker therapy, such as propranolol or nadolol, for inmates with large esophageal varices or red wale markings on endoscopy (The dose of beta-blocker should be

titrated weekly to reduce the resting heart rate by 25%, but not less than 55 beats/minute or reducing the systolic blood pressure to lower than 90 mm Hg.) Long-acting nitrates can be added to nonselective beta-blockers in patients who do not respond to beta-blockers alone, but long-acting nitrates should not be used alone;

- Primary prophylaxis for spontaneous bacterial peritonitis (SBP) with an antibiotic, such as ciprofloxacin, should generally be limited to short treatment periods in high risk patients such as those with upper gastrointestinal hemorrhage;

- Periodic screening for HCC by ultrasonography (e.g., annually) and alpha-fetoprotein testing (e.g. semiannually), but note, the optimal screening strategy is uncertain.

#### **ATTACHMENTS**

- Appendix 1: Contact Investigation - Acute Hepatitis A**
- Appendix 2: Inmate Fact Sheet - Hepatitis B and C Viral Infections**
- Appendix 3: Interpretation of Hepatitis B Virus Serologic Markers**
- Appendix 4: Evaluation Strategy for the Treatment of Chronic Hepatitis B**
- Appendix 5: Antiviral Medications for Chronic Hepatitis B**
- Appendix 6: Viral Hepatitis Vaccine Doses and Schedules**
- Appendix 7: Contact Investigation - Acute Hepatitis B**
- Appendix 8: Management for HBV Exposures**
- Appendix 9: Contraindications to Interferon or Ribavirin Therapy**
- Appendix 10: Evaluation Strategy for the Treatment of Chronic Hepatitis C**
- Appendix 11: Antiviral Medications for Chronic Hepatitis C**

- Appendix 12: Dosage Adjustment for Viral Hepatitis Medications
- Appendix 13: Contact Investigation - Acute Hepatitis C
- Appendix 14: Resources (Viral Hepatitis)
- Appendix 15: Provider Self-Assessment (Viral Hepatitis)



## Contact Investigation - Acute Hepatitis A

**Inmate name/number:** \_\_\_\_\_ **Date of report:** \_\_\_\_\_  
**Facility:** \_\_\_\_\_ **Date/facility entry:** \_\_\_\_\_  
**Date/BOP entry:** \_\_\_\_\_  
**Date of symptom onset:** \_\_\_\_\_  
**Reported by (name and title):** \_\_\_\_\_

Laboratory test	Result	Date
IgM anti-HAV		
IgM anti-HBc		
HBsAg		
anti-HCV	By GEIA GRNA GRIBA	
ALT/AST		

### 1. Reported to local health department?

GYes (date: \_\_\_\_\_) GNo (reason: \_\_\_\_\_)

### 2. In the 2-6 weeks prior to illness onset, was patient in a BOP facility?

GYes (complete BOP investigation necessary) GNo (local/state H.D. to do investigation, proceed to  
 “7. Contact notification”)

### 3. Risk factors (2-6 weeks prior to illness onset):

a) Did patient have close contact with a person with confirmed or suspected acute hepatitis A?

GYes GNo

Gsexual

Gcell mate

Gdorm mate

b) Illicit drug use? GYes GNo

c) Sexual partners? GYes (# \_\_\_\_\_) GNo

d) Work assignments:



**4. Detection and prevention of common source outbreaks:**

- a) Employed in food services? **G**Yes **G**No  
(If Yes, enhance case finding among persons eating at location)
- b) Part of a recognized common-source foodborne outbreak? **G**Yes **G**No

**5. Vaccination history:**

Vaccinated against hepatitis A? **G**No  
**G**Yes  
When? Dose #1 date:\_\_\_\_\_ Dose #2 date:\_\_\_\_\_

**6. Opportunities for prevention of this case:**

Was patient a cell or dormitory mate of a person with acute hepatitis? **G**Yes **G**No

**7. Contact evaluation for post-exposure prophylaxis:** Susceptible inmate contacts should ordinarily receive immunoglobulin (IG) prophylaxis, 0.02 mL/kg IM in the deltoid or gluteal muscle to prevent acute HAV infection within 2 weeks of exposure. Consult with local or State health department prior to administration.

**8. Susceptible contacts include:** cellmates, close personal contacts, injection drug use contacts, and sexual contacts. (Establish line listing).

**LINE LISTING - ACUTE HEPATITIS A**  
(Limited Official Use)

Cellmates, dorm mates, sexual contacts, persons sharing toilet facilities, etc.

G	Contact Name	Reg. Number	Date IG given

Food Service (FS) workers screened (screen **foodhandlers\*** in every case)

G	Potential Source Name/FS Contact	Reg. Number	IgM anti-HAV†	Date IG given¶

† if symptomatic

¶ if the index case is a **foodhandler\***

If **foodhandler\*** has acute hepatitis A: identify housing units/dorm/etc. with inmates eating food from location where foodhandler worked while ill and consider IG prophylaxis for inmates from these housing units (consult first with health department)

G	Housing unit/dorm/other identified area	Date IG given

\* **Foodhandler** - food service workers who prepare or touch the food before it is eaten.



## **INMATE FACT SHEET**

### **(Hepatitis B and Hepatitis C Viral Infections)**

#### **Am I at risk of being infected with hepatitis B virus (HBV) or hepatitis C virus (HCV)?**

- You may be at risk for HBV or HCV infection if you have ever injected drugs or had sex with an infected partner. HBV is more easily transmitted through sex and from a mother to her child compared to HCV. Persons receiving blood transfusions prior to 1992 may be at risk for HCV infection. Talk to a health care provider about the risks of infection that affect you personally.

#### **How can I prevent getting HCV or HBV while I am in prison?**

- Do not have sex with other inmates, shoot drugs, or get a tattoo or body piercing.  
 - Do not share toothbrushes, razors, nail clipping devices, or other personal items that might have blood on them with other inmates.

#### **Are these infections dangerous to my health?**

- Most persons infected with HBV or HCV do not develop serious health problems, however a small, but significant number of patients develop serious liver disease. Talk to a health care provider about your personal risks for developing liver disease.

#### **Why should I be tested for HBV or HCV infection?**

- You should be tested if you are at risk so doctors can monitor your infection and assess your need for treatment now or in the future. You should also be tested so that you can better prevent others from getting infected including your infant if you are pregnant.

#### **How do I get tested for HBV or HCV?**

- A simple blood test can determine if you are infected.

#### **How can I prevent giving HBV or HCV to others if I am already infected?**

- First, remember that you can spread these infections even if you feel fine.
- Do not shoot drugs or have sex with other inmates.
- Do not share personal items that might have your blood on them, such as toothbrushes, dental appliances, nail-clipping equipment or razors.
- Cover your cuts and skin sores to keep your blood from contacting other persons.
- If you are being released, talk to a health care provider about specific ways you can reduce the risk of spreading

HBV or HCV to others.

## INTERPRETATION OF HEPATITIS B VIRUS SEROLOGIC MARKERS\*

Serologic Markers				Interpretation
HBsAg	Total anti-HBc	IgM anti-HBc	Anti-HBs	
-	-	-	-	Susceptible, never infected
+	-	-	-	Acute infection, early incubation **
+	+	+	-	Acute infection <sup>§</sup>
-	+	+	-	Acute resolving infection <sup>§</sup>
-	+	-	+	Past infection, recovered and immune
+	+	-	-	Chronic infection
-	+	-	-	Multiple interpretations <sup>¶</sup>
-	-	-	+ ≥10 mIU/mL	Immune from vaccination

\*Adapted from CDC guidelines, Recommendations for preventing transmission of bloodborne pathogen infections among chronic hemodialysis patients, *MMWR* 2001;50(RR-5):1-43.

\*\* **NOTE:** Transient HBsAg positivity (lasting < 21 days) might be detected in some patients during vaccination

<sup>§</sup> IgM usually wanes after 6 months post-infection, but may persist for up to 2 years.

<sup>¶</sup> Remote infection (anti-HBs may be absent since it wanes with time and may disappear with remote history of infection), a false positive test (i.e., susceptible), resolving acute infection, or “low-level” chronic infection.

**HBsAg** is hepatitis B surface antigen.

**Total anti-HBc** is total antibody to hepatitis B core antigen.

**IgM anti-HBc** is the immunoglobulin M antibody to hepatitis B core antigen.

**Anti-HBs** is antibody to hepatitis B surface antigen.



## EVALUATION STRATEGY TREATMENT OF CHRONIC HEPATITIS B

### Diagnose chronic hepatitis B

HBsAg+ 6 - 12 months

↓

HBeAg+/HBV DNA+; OR  
HBeAg-/HBV DNA+

↓

### Baseline evaluation

Counseling/history and physical examination/assess alcohol use and substance abuse

Refer to drug education and treatment programs as appropriate

If decompensated cirrhosis is present → consider lamivudine

If decompensated cirrhosis is not present → monitor ALT

↓

### ALT monitoring

If ALT is normal → monitor ALT every 3-6 months

If ALT is elevated above upper limit of normal → confirm ALT elevation over 3-6 months

IF ALT elevation is confirmed and HBV DNA is  $> 10^5$  cps/mL refer for liver biopsy

↓

### Liver biopsy

Normal biopsy/minimal inflammation → monitor HBe/HBsAg/repeat biopsy

Evidence of liver necroinflammation  $\geq 4$  → consider drug therapy

↓

### Antiviral Drug therapy

Drug therapy should be patient-specific → Consider:

degree of liver disease/HBe status/co-morbid conditions/prior treatment history

**NOTE:** The long-term benefits of antiviral therapy for chronic hepatitis B are uncertain. The decision to recommend treatment for chronic hepatitis B should be based on the severity of liver disease, the likelihood of response, co-morbid conditions, and the potential for adverse reactions. The specific treatment regimen should be determined on a case-by-case basis (see text).

## ANTIVIRAL MEDICATIONS FOR CHRONIC HEPATITIS B

Medication	Dosage	Baseline tests	Monitoring**	Toxicities	Comments
<b>Interferon alfa</b> (2a or 2b)  (Roferon-A) (Intron-A)	5 million units SC daily; OR 10 million units SC 3x/week - for 16-24 weeks  HBeAg-negative patients require longer duration, e.g. ≥ 12 months	anti-HIV, anti-HCV anti-HDV  HBeAg, HBV DNA ALT/AST, liver function CBC (with diff and plts) chemistry panel creatinine/BUN thyroid function studies mental health assessment	clinician evaluations every week X 1 month then monthly  CBC (with diff and plts) ALT/liver function creatinine/BUN, TSH  psychology/psychiatry monitoring as necessary	fever fatigue myalgia psychiatric (rage, confusion, depression) bone marrow suppression thyroid dysfunction renal failure	contraindicated with decompensated cirrhosis  drug interaction: concomitant use of interferon alfa-2b significantly increases theophylline levels
<b>Lamivudine</b> (Epivir-HBV®)	100 mg orally, daily for 1 year or more  drug resistance may develop	same as above except thyroid studies and mental health assessment only necessary if clinically indicated	clinician evaluations every week X 1 month then monthly  ALT/liver function creatinine/BUN	lactic acidosis hepatomegaly/steatosis pancreatitis	some improvement possible with decompensated cirrhosis  higher dose as part of HAART* regimen in HIV-coinfected patients
<b>Adefovir dipivoxil</b> (Hepsera®)	10 mg orally, daily  optimal duration is uncertain; tx for at least 48 weeks; hepatitis may worsen when drug tx is stopped	same as above except thyroid studies and mental health assessment only necessary if clinically indicated	clinician evaluations every week X 1 month, then monthly  ALT/liver function creatinine/BUN	renal failure - seen with higher doses  lactic acidosis hepatomegaly/steatosis HIV resistance	a HAART* regimen is recommended for persons with HBV/HIV co-infections treated with adefovir  medication well tolerated and drug resistance does not develop

\*HAART is highly active antiretroviral therapy.

\*\*See monitoring parameters in Guidelines text.

## VIRAL HEPATITIS VACCINE DOSES AND SCHEDULES

### Hepatitis A and B Vaccines for Adults

Virus/Vaccine Type	Dose (mL)	Volume Doses	No. of (months)	Schedule
<b>Hepatitis A</b>				
Havrix <sup>†</sup>	1,440 EL.U. * ^	1.0	2	0 and between 6 - 12
VAQTA <sup>§</sup>	50 U ^	1.0	2	0 and between 6 - 12
<b>Hepatitis B</b>				
Recombivax-HB <sup>§</sup>	10 mcg ^	1.0	3	0, 1, and 6
Engerix-B <sup>†</sup>	20 mcg ^	1.0	3	0, 1, and 6
<b>Hepatitis A and B combination</b>				
Twinrix <sup>†</sup>	20 mcg (B ) ^ 720 EL.U. (A)	1.0	3	0, 1, and 6

**Source:** Adapted from CDC guidelines, *MMWR* 2003;52(No. RR-1)

### Hepatitis B Vaccines for Hemodialysis-dependent Adults

Virus/Vaccine Type	Dose (mL)	Volume Doses	No. of (months)	Schedule
<b>Hepatitis B</b>				
Recombivax-HB <sup>§</sup>	40 mcg ^	1.0	3	0, 1, and 6
Engerix-B <sup>†</sup>	40 mcg ^	2.0 <sup>¶</sup>	4	0, 1, 2, and 6

**Source:** Adapted from CDC guidelines, *MMWR* 2001;50( No. RR.- 5)

<sup>†</sup> Manufactured by GlaxoSmithKline Biologicals

<sup>§</sup> Manufactured by Merck & Co., Inc.

\* Enzyme linked immunosorbent assay (ELISA) units.

<sup>¶</sup> Two 1.0 mL doses administered at one site in a 4-dose schedule at 0, 1, 2, and 6 months.

^ Recommended route/site for administration is the deltoid by intramuscular injection.

## CONTACT INVESTIGATION - ACUTE HEPATITIS B

Inmate name/number: \_\_\_\_\_

Date of report: \_\_\_\_\_

Facility: \_\_\_\_\_

Date/facility entry: \_\_\_\_\_

Date/BOP entry: \_\_\_\_\_

Date of symptom onset: \_\_\_\_\_

Reported by (name and title): \_\_\_\_\_

Laboratory test	Result	Date
IgM anti-HAV		
IgM anti-HBc		
HBsAg		
anti-HCV	By GEIA GRNA GRIBA	
ALT/AST		

**1. Reported to local health department?**

GYes (date: \_\_\_\_\_) GNo (reason: \_\_\_\_\_)

**2. In the 6 weeks-6 months prior to illness onset, was patient in a BOP facility?**

GYes (complete BOP investigation necessary) GNo (local/state H.D. to do investigation)

**3. Risk factors (6 weeks - 6 months prior to illness onset):**

a) Did patient have close contact with a person with confirmed or suspected HBV infection?

GYes

GNo

Gsexual

Gcell mate

Gdorm mate

Gother (specify: \_\_\_\_\_)

(If known contact, evaluate prior opportunities for immunoprophylaxis)

b) Injection drug use? GYes GNo

c) Sexual partners? GYes (# \_\_\_\_\_) GNo

d) Other reported contact with human blood? GNo

- G**Yes (when/what circumstances? \_\_\_\_\_)
- e) On dialysis? **G**Yes **G**No  
**G** Dialysis center notified
- f) Recent hospitalization? **G**No  
**G**Yes (When? Where? \_\_\_\_\_)
- g) Recent IV infusions or injections received in outpatient setting? **G**No  
**G**Yes (When? Where? \_\_\_\_\_)
- h) Recent dental work **G**No  
**G**Yes (When? Where? \_\_\_\_\_)
- i) Recent tattoo **G**Yes **G**No
- j) Body piercing **G**Yes **G**No

#### 4. Vaccination history:

- Vaccinated against hepatitis B? **G**No  
**G**Yes  
 When? Dose #1 date: \_\_\_\_\_ Dose #2 date: \_\_\_\_\_ Dose #3 date \_\_\_\_\_

#### 5. Review prior opportunities for prevention of this case:

- a) Was patient a cell or dormitory mate of a person with acute hepatitis? **G**Yes **G**No

**6. Contact evaluation:** Consider total anti-HBc testing to determine contacts' susceptibility.

**7. Contact management:** Inmates in close contact with an inmate diagnosed with acute hepatitis B should be considered for post-exposure prophylaxis.

**NOTE:** For susceptible inmate contacts with identified or suspected per cutaneous or mucosa exposures, administer post-exposure prophylaxis by initiating the first dose of hepatitis B vaccine series IM in the deltoid muscle along with HBIG 0.06 ml/kg body weight IM at a separate site (Give HBIG only if within 7 days of exposure).

**NOTE:** For susceptible inmate contacts without identified or suspected per cutaneous or mucosa exposures, initiate the first dose of hepatitis B vaccine, but do not give HBIG.

**NOTE:** Contacts include: injection drug use contacts, sexual contacts, tattoo contacts, and close personal contacts (Establish line listing).

**LINE LISTING - HEPATITIS B**  
(Limited Official Use)

Suspected per cutaneous or mucosa exposure:

<b>G</b>	Contact Name	Reg. Number	Date BIG given	Date vaccinated

Close contacts (i.e., cellmates, sharing of personal items, etc.) without identified percutaneous/mucosal exposure (i.e., ring vaccination):

<b>G</b>	Contact Name	Reg. Number	Date vaccine series initiated



### Management of Hepatitis B Virus Exposures\*

Vaccination Status/Antibody Status	Treatment Based on Source's HBsAg Status		
	HBsAg positive	HBsAg negative	Unknown Status
Unvaccinated	HBIG** X 1; Initiate HB vaccine series	Initiate HB vaccine series	Initiate HB vaccine series
Vaccinated - known responder Adequate anti-HBs is $\geq 10$ mIU/ml	No treatment	No treatment	No treatment
Vaccinated - known nonresponder	HBIG X 1 and revaccination series, OR HBIG X 2 ***	No treatment	Treat as if source were HBsAg-positive
Vaccinated - unknown response status	Test exposed person for anti-HBs: If adequate - no tx  If inadequate - HBIG X 1 PLUS vaccine booster	No treatment	Test exposed person for anti-HBs: If adequate - no tx  If inadequate - give vaccine booster/recheck titer in 1 - 2 months

\* Exposure is percutaneous (laceration, needlestick, bite) or permucosal (ocular or mucous-membrane) contact with blood.

\*\* HBIG dose is 0.06 mL/kg administered IM at different site than vaccine, preferably < 24 hours after exposure, but no greater than 7 days post-exposure.

\*\*\* Give 1 dose of HBIG and reinitiate vaccine series for nonresponders who have not completed second 3-dose vaccine series;

Give HBIG X 2 for nonresponders who have failed second vaccine series

Adapted from CDC guidelines, Updated U.S. Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for post-exposure prophylaxis. *MMWR* 2001;50(RR-11):1-52.



## CONTRAINDICATIONS FOR INTERFERON/ RIBAVIRIN THERAPY\*

### INTERFERON

(standard and pegylated)

#### Absolute Contraindications:

- Decompensated cirrhosis
- Hypersensitivity to interferon
- Solid organ transplantation
- Active suicidal ideation or other neuropsychiatric condition that is poorly controlled
- Ongoing alcohol or illicit drug usage - refer for evaluation

#### Relative Contraindications:

- Age > 60 years
- Bone marrow dysfunction - neutropenia/thrombocytopenia
- Hepatitis B co-infection
- HIV infection with acquired immunodeficiency syndrome (AIDS)
- Diabetes that is poorly controlled
- Renal insufficiency; creatinine clearance < 50 ml/min
- History of recent alcohol abuse or illicit drug usage - refer for evaluation

### RIBAVIRIN

#### Absolute Contraindications

- Pregnancy - due to risk of fetal malformations and fetal death; pregnancy test required
- NOTE: women of childbearing potential AND men must use two forms of effective contraception during treatment and during the six-months post-treatment**
- Hemoglobinopathies, hemolytic anemias or other severe anemias
- Ischemic cardiovascular disease or cerebrovascular disease
- Renal insufficiency - creatinine clearance < 50 ml/min

\*Refer to drug manufacturers' warnings in addition to highlighted contraindications

## **EVALUATION STRATEGY FOR TREATMENT OF CHRONIC HEPATITIS C**

### **Screen for HCV infection**

**EIA+ or CIA+ for high risk inmates**

**EIA+ or CIA+ supplemented by RIBA+ for low risk inmates**

**OR**

**EIA+ or CIA+ with high signal-to-cutoff ratio - no RIBA required**

**EIA+ or CIA+ with low signal-to-cutoff ratio - confirm with supplemental RIBA+**

↓

### **Conduct baseline evaluation**

**Medical history/assess alcohol use/substance abuse/counseling on risk reduction**

**Refer to drug education/drug treatment programs as appropriate**

**Physical examination/basic lab studies including liver enzymes/function studies**

**Evaluate other potential causes of liver disease as appropriate**

**Evidence of decompensated cirrhosis - manage without antiviral therapy**

↓

### **Review contraindications to antiviral treatment**

**Assess contraindications to interferon and ribavirin prior to liver biopsy**

**Mental health assessment**

↓

### **Assess ALT measurements**

**If ALT is two times normal or greater - confirm elevation and refer for liver biopsy**

**If ALT is persistently normal or < 2 times normal - biopsy selectively - (see text)**

**If evidence of compensated cirrhosis - consider liver biopsy or treat empirically**

↓

### **Confirm chronic HCV infection prior to liver biopsy**

**Detect HCV RNA by qualitative NAT assay with threshold of < 50 IU/mL**

↓

### **Stage liver disease and assess indications for treatment**

**Liver biopsy to assess degree of fibrosis and inflammation (see text)**

**If liver biopsy is normal or shows minimal fibrosis - monitor/rebiopsy in 1-5 years**

**If liver biopsy shows portal or bridging fibrosis and moderate inflammation and necrosis -  
consider antiviral therapy**

↓



**Determine HCV genotype and test for HCV RNA prior to treatment**

Determine HCV genotype

If genotype 1 - obtain quantitative HCV RNA assay

If genotype 2 or 3 - obtain qualitative HCV RNA assay

↓

**Review and complete relevant studies and evaluations prior to treatment**

Physician evaluation and review of liver enzymes, bilirubin, albumin, prothrombin time

Serum chemistries/CBC/platelet count/thyroid function studies

Ferritin/ANA/other liver diagnostic studies as appropriate

Pregnancy test for all females

Cardiac risk assessment

Mental health assessment

↓

**Initiate antiviral drug therapy**

(HCV Genotype 2 or 3)

Treat with pegylated interferon/ribavirin combination therapy for 24 weeks and;  
check qualitative HCV RNA at completion of treatment.

(HCV Genotype 1)

Treat with pegylated interferon/ribavirin therapy and;  
check HCV RNA quantitative assay after 12 weeks.

If viral levels have not decreased by 2 logs ( $10^2$ ) at 12 weeks - discontinue therapy;  
otherwise continue therapy for 48 weeks.

Check HCV RNA assay at completion of treatment

(All Genotypes - if ribavirin contraindicated)

Treat with pegylated interferon for 48 weeks

Monitor like genotype 1 patients on combination therapy

↓

**Monitor post-treatment**

Repeat ALT every 2 months for 6 months after completion of effective therapy

Measure HCV RNA 6 months after completion of effective therapy

Referral to drug education/tx program if appropriate and not previously completed

### Antiviral Medications for Chronic Hepatitis C - Interferon Preparations

Medication	Dosage	Baseline tests	Monitoring	Toxicities	Comments
<b>Interferon alfa (2a or 2b)</b>  (Roferon-A®) (Intron-A®)	3 million units SC 3x/week	history and physical ALT, AST, bilirubin, albumin, alkaline phosphatase PT/INR  CBC (with diff and plts) chemistry panel creatinine/BUN thyroid function studies ferritin/ANA	clinician evaluations (every week X 1 month, then monthly)  ALT at weeks 1, 2, 4, and 8-12 weeks thereafter	fever fatigue myalgia  neuropsychiatric (rage, confusion, depression, suicide)	pegylated interferon in combination with ribavirin is the recommended treatment regimen for chronic hepatitis C for most patients
<b>Pegylated Interferon alfa-2b</b>  (PEG-Intron®)	1.5 mcg/kg SC q week with ribavirin  1.0 mcg/kg SC q week when used as monotherapy	anti-HIV HBsAg  liver biopsy HCV genotype HCV RNA NAT	CBC (with diff and plts), at weeks 1, 2, 4, and 4-8 weeks thereafter  TSH every 3 months  renal and liver function studies periodically; and whenever clinically warranted	bone marrow suppression thyroid dysfunction renal failure	peginterferon alfa-2b (PEG-Intron®) is available only via the PEG-Intron Access Assurance Program
<b>Pegylated Interferon alfa-2a</b>  (PEGASYS®)	180 mcg SC q week	psychologic/psychiatric evaluation	screen for depression psych/psych evaluations as clinically needed		Patients with compensated cirrhosis and HIV co-infection may have more severe adverse effects: monitor hematologic parameters closely

## Antiviral Medications for Chronic Hepatitis C - Ribavirin Preparations

Medication	Dosage	Baseline Tests	Monitoring	Toxicities	Comments
<b>Ribavirin</b> with interferon 200mg caps (REBETOL®)	$\leq 75$ kg: 400 mg PO q AM 600 mg PO q PM  $>75$ kg: 600mg PO BID	CBC with diff and platelets; see baseline tests for interferon since ribavirin always given in combination with interferon preparation	ongoing monitoring of hemoglobin and hematocrit for evidence of hemolytic anemia, which often occurs between 1 and 4 weeks after initiating therapy.	hemolysis - expect 5% - 10% decrease in hematocrit  NOTE: patients with cirrhosis may have more severe anemia	ribavirin capsules should be taken with food  <b>ribavirin should be administered on pill line to ensure compliance and increase efficacy</b>
<b>Ribavirin<sup>1,2</sup></b> (/pegylated interferon)	<u><b>REBETOL®</b></u> genotype 2 or 3: 400 mg PO BID  genotype 1: same dosages as used when combined with nonpegylated IFN  <u><b>COPEGUS®</b></u> genotype 1 or 4: $<75$ kg = 400 mg PO qAM 600 mg PO qPM $>75$ kg = 600 mg PO BID  genotype 2 or 3: 400 mg PO BID	<b>pregnancy test for all female inmates</b>	<b>NOTE: women of childbearing potential AND men must use two forms of birth control during treatment AND during the 6 months after antiviral therapy is completed.</b>  consider monthly pregnancy tests for female inmates at risk of pregnancy, e.g., community access	NOTE: anemia may precipitate angina, dyspnea, fatigue  <b>teratogenic</b> - counsel women AND men regarding the risk of birth defects and the necessity of birth control before, during, and after treatment is completed.  counseling is particularly important for inmates awaiting release.	the optimal dose of ribavirin depends on HCV genotype, i.e., higher doses are required for genotype 1  ribavirin should not be used in patients with a creatinine clearance of $<50$ ml/min

<sup>1</sup>COPEGUS® and REBETOL®, are formulated as tablets and capsules respectively; and are considered to be bioequivalent by the FDA.

<sup>2</sup>In clinical studies pegylated interferon alfa-2a was administered with COPEGUS ® and pegylated interferon alfa-2b was administered with REBETOL®.

## DOSAGE ADJUSTMENTS FOR VIRAL HEPATITIS MEDICATIONS

Medication	Parameter	Adjustment
<b>Lamivudine</b>	creatinine clearance (mL/min) $\geq$ 50	100 mg/day
	30-49	100 mg first dose, then 50 mg/day
	15-29	100 mg first dose, then 25 mg/day
	5-14	35 mg first dose, then 15 mg/day
	<5	35 mg first dose, then 10 mg/day
<b>Interferons</b>	WBC < 1500 neutrophil ct < 750 platelet ct < 80,000	reduce dose by 50%
<b>Ribavirin</b>	hemoglobin < 10g/dl	reduce dose to 200 mg AM, 400 mg q HS
<b>Ribavirin and Interferons</b>	hemoglobin < 8.5 g/dL WBC < 1000 neutrophil ct < 500 platelet ct < 50,000	discontinue
<b>Special patients: For inmates with history of cardiac disease (CHF, previous history of MI, angina, or known coronary artery disease by angiography)</b>		
<b>Ribavirin</b>	2 g/dL drop in hemoglobin during any four week period of treatment.	reduce dose to 200 mg AM, 400 mg q HS
<b>Interferon</b>		reduce dose by 50%
<b>Ribavirin and Interferons</b>	hemoglobin < 12 g/dL after 4 weeks at reduced dose above	discontinue

## Contact Investigation - Acute Hepatitis C

**Inmate name/number:** \_\_\_\_\_ **Date of report:** \_\_\_\_\_  
**Facility:** \_\_\_\_\_ **Date/facility entry:** \_\_\_\_\_  
**Date of symptom onset:** \_\_\_\_\_ **Date/BOP entry:** \_\_\_\_\_  
**Reported by (name and title):** \_\_\_\_\_

Laboratory test	Result	Date
IgM anti-HAV		
IgM anti-HBc		
HBsAg		
anti-HCV	By GEIA GRNA GRIBA	
HCV RNA (qual. or quant.)		
ALT/AST		

### 1. Reported to local health department?

**G**Yes (date: \_\_\_\_\_) **G**No (reason: \_\_\_\_\_)

### 2. In the 2 weeks-6 months prior to illness onset, was patient in a BOP facility?

**G**Yes (complete BOP investigation necessary) **G**No (local/state H.D. to do investigation)

### 3. Risk factors (2 weeks - 6 months prior to illness onset):

a) Did patient have close contact with a person with confirmed or suspected HCV infection?

**G**Yes **G**No

**G**sexual

**G**cell mate

**G**dorm mate



**G**other (specify: \_\_\_\_\_)  
(If known contact, evaluate prior opportunities for immunoprophylaxis)

- b) Injection drug use?      **G**Yes      **G**No
- c) Sexual partners?    **G**Yes (# \_\_\_\_\_)      **G**No
- d) Other reported contact with human blood? **G**No  
    **G**Yes (when/what circumstances? \_\_\_\_\_)
- e) On dialysis? **G**Yes      **G**No  
    **G** Dialysis center notified
- f) Recent hospitalization? **G**No  
    **G**Yes (When? Where? \_\_\_\_\_)
- g) Recent IV infusions or injections received in outpatient setting? **G**No  
    **G**Yes (When? Where? \_\_\_\_\_)
- h) Recent dental work **G**No  
    **G**Yes (When? Where? \_\_\_\_\_)
- i) Recent tattoo **G**Yes      **G**No
- j) Body piercing **G**Yes      **G**No

**4. Prior opportunities for prevention of this case:**

Was patient a cell or dormitory mate of a person with acute hepatitis? **G**Yes    **G**No

**5. Contact notification** (HCV counseling and testing should be offered and line listing established):

**LINE LISTING - ACUTE HEPATIS C**  
**(Limited Official Use)**

[illegible]

## **RESOURCES**

### **(Prevention and Treatment of Viral Hepatitis)**

**National Institutes of Health**  
**National Digestive Diseases Information Clearinghouse**  
<http://www.niddk.nih.gov>  
**1-301-654-3810**

**Centers for Disease Control and Prevention**  
**1-888-443-7232**  
**(4HEPCDC)**  
<http://www.cdc.gov/ncid>

**National Clinicians' Post-Exposure Prophylaxis Hotline**  
**1-888-448-4911**

## **PROVIDER SELF-ASSESSMENT**

### **(Prevention and Treatment of Viral Hepatitis)**

**Question #1**

Which of the following statements is FALSE regarding the transmission of viruses that cause hepatitis?

- A. HAV is spread by fecal-oral contact.
- B. HBV, HCV, and HIV are all transmitted by percutaneous exposures.
- C. HCV was not readily transmitted by blood transfusions after 1992.
- D. HDV can not cause chronic infection and hepatitis without the presence of HBV.
- E. HBV infection is not a sexually transmitted disease.

**Question #2**

Which of the following is FALSE regarding HBV infection?

- A. Persons with chronic HBV infection (HBsAg-positive) are potentially contagious.
- B. Most persons acutely infected with HBV will develop chronic hepatitis.
- C. Persons with chronic HBV infection sometimes clear HBV infection without treatment.
- D. Anti-HBs protects a person from new HBV infections.

**Question #3**

An inmate who is HBsAg-positive shares his tattoo needle with 4 other inmates who have never been vaccinated for hepatitis B and all have unknown immunity to HBV infection. Which of the following statements is false regarding the management of the exposed inmates in this setting?

- A. Immediate treatment with hepatitis B immunoglobulin (HBIG) is warranted.
- B. The hepatitis B vaccine series should be initiated concurrently with HBIG.
- C. If the exposures occurred 3 months ago HBIG will still be effective.
- D. Both HBIG and hepatitis B vaccine are indicated for exposed HIV seropositive inmates.

**Question #4**

Which of the following is FALSE regarding HCV infection?

- A. RIBA testing is usually necessary for screening inmates with a positive EIA for anti-HCV.
- B. Persons with antibodies to HCV may have chronic HCV infection.
- C. A subset of persons acutely infected with HCV will not develop chronic HCV infection.
- D. Detecting HCV RNA by a nucleic acid test is necessary before initiating drug therapy.

**Question #5**

Which of the following is FALSE regarding interferon/ribavirin therapy for hepatitis C?

- A. Hemolysis from ribavirin is a common side effect.
- B. Ribavirin can be given as monotherapy if interferon is contraindicated.
- C. A flu-like syndrome should be anticipated with initiation of interferon therapy.
- D. Ribavirin may cause birth defects even in a woman who has just stopped taking ribavirin.

**Question #6**

Which of the following statements is FALSE regarding the natural history of hepatitis C?

- A. Most persons with chronic HCV infection will not develop cirrhosis.
- B. Persons with a history of heavy alcohol use are more likely to develop cirrhosis.
- C. Persons with HIV infection and chronic HCV infection are more likely to develop cirrhosis.
- D. The HCV genotype determines which persons with HCV infection will develop cirrhosis.

**Question #7**

Which of the following statements is FALSE regarding antiviral therapy with pegylated interferon and ribavirin for chronic hepatitis C?

- A. The likelihood of responding to treatment does not depend on genotype.
- B. The duration of treatment does depend on the HCV genotype.
- C. Persons have a better response to antiviral treatment if cirrhosis has not developed.
- D. Some patients may have undetectable HCV RNA 6 months after treatment.

**Question #8**

Which of the following statements is FALSE regarding cirrhosis and chronic HCV infection?

- A. Beta-blockers prevent bleeding in persons with cirrhosis and large esophageal varices.
- B. A patient with hepatic encephalopathy is a good candidate for antiviral therapy.
- C. Peritonitis may be the source of fever in a person with marked ascites.
- D. Persons with chronic HCV infection and cirrhosis are at risk for hepatocellular carcinoma.

Provider Self-Assessment - Answers  
(Viral Hepatitis)

**1. - E**

**2. - B**

**3. - C**

**4. - A**

**5. - B**

**6. - D**

**7. - A**

**8. - B**